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There is abundant evidence suggesting that Major Depressive Disorder (MDD) is closely 
related to thyroid hormone (TH) function, but the exact nature of this relationship is 
poorly defined in the literature. The present study examined whether hypothyroidism 
could viably model symptoms of MDD in mice using established behavioral paradigms. 
It was expected that hypothyroidism would produce anhedonia-like behavior in the 
saccharin preference test, anxiety-like behavior in the elevated plus maze, and spatial 
memory impairment in the object placement task. C57BL/6J mice were randomly 
assigned to one of three groups, which received either a control diet, diet infused with 6-
propyl-2-thiouracil (hypothyroid group), or a combination of 6-propyl-2-tiouracil and 
thyroxine (hyperthyroid group). Each group had ad libitum access to food and water for 4 
weeks prior to behavioral assessment. Contrary to our hypothesis, hypothyroid mice did 
not exhibit more anhedonia or greater spatial memory impairment than controls. 
However, they did spend a significantly lower percentage of time in the open arms of the 
elevated plus-maze compared to both the control and hyperthyroid groups.  Additionally, 
hyperthyroidism was associated with increased preference for sweetened water over tap 
water in the saccharin preference test.  These findings raise interesting questions about 
how TH could regulate specific components of the depressive phenotype, which will be 
discussed at length. This project also lays the groundwork for a larger investigation of 
glutamate neurotransmission in hypothyroidism-induced depression. As a future 
extension of this research, AMPA receptor binding will be examined in the obtained 
cortical and hippocampal tissue so that relationships between depressive behaviors, 
thyroid status, and glutamatergic activity can be explored in a truly integrated fashion.  
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Examining a Hypothyroid Model of Depressive Symptoms in Mice:  
Tests of Behavioral Measures 
 
Major depressive disorder (MDD) affects over 300 million people worldwide and 
is the leading cause of disability across the globe (World Health Organization, 2018). 
This psychiatric disorder takes a major toll at both the individual and societal levels, 
leading to severe public health and socioeconomic burdens. The cost of the disorder – 
through both treatment expense and loss of productivity –has been estimated to be $210 
billion per year worldwide (Aleksandrova, Phillips, & Wang, 2017) and $36.6 billion in 
the United States alone (Kessler et al., 2006). In a sample of 9,282 adults in the US 
workforce, major depression was associated with an annual average of 27.2 lost work 
days and $4,426 lost capital per capita. These losses do not fully reflect the social, 
emotional, and cognitive turmoil that accompany the disorder. Mortality rates are high 
with an estimated 800,000 deaths by suicide per year, and the World Health Organization 
lists suicide as the second leading cause of death in the 15- to 29-year-old demographic 
(2018). 
Despite the high number of antidepressants available on the market and the 
general perception that modern antidepressant treatments are effective, these treatments 
have important limitations that must be addressed. The percentage of patients who 
clinically benefit from antidepressant treatment is shockingly small. In one of the largest 
and studies evaluating antidepressant treatments (STAR*D), it was reported that only 
about one-third of patients experienced remission after 4 months of treatment with 
standard SSRIs while another 30% were only partially responsive (Rush et al., 2006). 
Other large-scale studies have yielded similar concerning findings (e.g. Thase et al., 
2005), with one reporting only 28% remission in a sample of over 2,800 patients (Trivedi 




et al., 2006). Furthermore, standard antidepressants notably take an average of 6-8 weeks 
to show any clinical benefit in patients who do respond. This delay in efficacy is 
especially problematic given that suicide attempts are at increased risk during the first 
month of treatment (Murrough, 2012). It is thus widely agreed upon in the literature that 
although antidepressant drugs are generally thought to be effective, the low response rate 
and slow efficacy onset featured by these treatments represent important unmet needs for 
MDD patients that must be addressed. 
One major challenge to this advancing pharmacological treatments for MDD is 
that the despite decades of research, the pathophysiology underlying MDD remains 
relatively unclear. Heterogeneity of symptoms, lack of consistent biomarkers, and 
interaction with socio-environmental variables all likely contribute to the poor 
understanding of its mechanisms (Duman & Aghajanian, 2012).  
In the present study, the investigation of thyroid hormone (TH) effects on 
depressive symptoms was conducted in order to elucidate the disorder’s underlying 
etiological processes. There is abundant evidence suggesting that depression is closely 
related to TH function; for example, hypothyroidism is significantly more prevalent 
among depressed patients than the general population, with one study reporting 
hypothyroidism in 52% of treatment-resistant depressed patients compared to 5% of the 
non-depressed controls (Wu, Chien, Lin, Chou, & Chou, 2013). The prevalence of 
depression among hypothyroid patients has additionally been reported to be as high as 
63% (e.g. Chaudhary, Chabra, Singla, Mishra, & Sharma, 2014; Bathla, Singh, & Relan, 
2016), which suggests that low TH levels are associated with depressive symptoms. 
However, the precise nature of the relationship between hypothyroidism and specific 




MDD symptoms remains poorly defined in the literature – likely due to the great 
complexity of both disorders and methodological differences across studies. It was our 
hope that further clarity about TH’s specific role in depressive behaviors would, in turn, 
provide further clarity about the processes behind the depressive behaviors themselves.  
Recent work in the depression literature has highlighted the importance of 
intracellular signaling cascades, neuroplasticity, and synaptogenesis-induced activity in 
the neuropathology of MDD (e.g. Machado-Vieira et al., 2009; Duman & Aghajanian, 
2012). Thyroid hormones, which regulate metabolism, growth, and development in 
virtually every cell in the body, are highly likely to be implicated in the dysfunction of 
these processes. Another notable line of research has identified the glutamatergic system 
as an important target for antidepressant action; a system which, importantly, has been 
found to be regulated by TH activity as well (e.g. Mendes-de-Aguiar et al., 2008; Zarif, 
Petit-Paitel, Heurteaux, Chabry, & Guyon, 2016). Support for the role of glutamate in 
MDD comes from reports of robust antidepressant properties of ketamine, which is an 
antagonist of the glutamate receptor N-methyl-D-aspartate (NDMA). In a groundbreaking 
and widely replicated clinical study, Berman et al. (2000) demonstrated that a single low 
dose of ketamine significantly reduced symptoms in treatment-resistant MDD patients in 
only 72 hours. Ketamine itself is associated with dissociative and psychotomimetic side 
effects that make it an inappropriate treatment for MDD (Aleksandrova et al., 2017), but 
examining the mechanisms behind its rapid effects can aid in the identification of new 
drug targets and more effective treatments. Subsequent studies have used ketamine to 
investigate potential roles of the glutamate receptor AMPA, the inhibitory 
neurotransmitter GABA, NMDA-mediated long-term potentiation (LTP) processes, and 




factors important for cell growth like brain-derived neurotrophic factor (BDNF). The 
following review outlines how each of these factors relate not only to the pathology of 
depression, but also to the various components of thyroid function. 
 
Literature Review 
Relationships between thyroid conditions and psychiatric disorders have long 
been observed, and records of these observations can be traced back as early as 1786 
(Bahls & Carvalho, 2004). In 1949, Asher published descriptions of 14 clinical cases 
where hypothyroidism accompanied severe melancholic and psychotic states – a 
condition that he termed “myxedema madness.” Importantly, treatment of the 
hypothyroidism with thyroid hormones (THs) alleviated the psychiatric symptoms as well 
(Asher, 1949). Several lines of empirical research since then have similarly examined the 
hypothyroid-mood relationship. Many of the resulting findings – such as antidepressant-
like properties of THs, abnormal TH levels among depressed patients, and depressive 
symptoms associated with hypothyroidism – support our hypothesis that induced 
hypothyroidism can model MDD symptoms in animal studies. Since the present research 
is being done in the context of finding more effective antidepressant treatments, research 
that explores the underlying mechanisms THs and MDD have in common is particularly 
relevant. The following review examines some of the work that forms the basis of this 
project. 
Overview of the Hypothalamic-Pituitary-Thyroid (HPT) Axis 
First, it is crucial to have a basic understanding of THs and their production, 
secretion, and function throughout the body. THs are regulated through a complex 
interplay of hormones in the hypothalamic-pituitary-thyroid axis (Figure 1). Briefly, 




neurons in the hypothalamus produce thyrotropin-releasing hormone (TRH) which is 
released to thyroroph cells in the anterior pituitary. This stimulates the synthesis and 
release of thyroid stimulating hormone (TSH); which, in turn, stimulates TH production 
in the thyroid gland. High levels of thyroid hormone in the bloodstream reduces the 
sensitivity of pituitary thyrotropes to TRH, which decreases the rate at which TSH is 
secreted. In this way, THs regulate TSH synthesis through a negative feedback loop (Rao 
et al., 1996; Nussey & Whitehead, 2001). Abnormal levels of any one of these hormones 
– as well as irregularities in any of their many receptors, enzymes, and protein 
transporters – can therefore threaten the careful maintenance of this system (Hage & 
Azar, 2012). Indeed, as this review will address, there are several different ways by 
which TH function is reportedly altered in depressed patients. 
The two major THs produced in the thyroid gland are triiodothyronine (T3) and 
thyroxine (T4). Production starts with iodide ions being actively transported from the 
plasma to follicular cells in the thyroid, where they are oxidized by the enzyme 
thyroperoxidase (TPO) to form atomic iodine molecules (Nussey & Whitehead, 2001).  
TPO is also responsible for using these molecules to iodinate the tyrosine residues of 
thyroglobulin, which is a glycoprotein synthesized in the thyroid follicles. Once 
iodinated, adjacent tyrosine residues combine with one another (a process also initiated 
by TPO) to form the thyroid hormones. Combinations containing three iodides result in 
the hormone T3, while combinations containing four iodides result in T4 (Nussey & 
Whitehead, 2001). With regard to the HPT axis, TSH influences TH levels by stimulating 
various processes essential for TH synthesis such iodine uptake, production of the 
enzyme TPO, and the release of TH into the bloodstream. 




 TH mechanisms of action. Once THs are released by the thyroid into the 
bloodstream, their actions continue to be dependent on a number of factors. One such 
factor is the conversion of T4 into T3. Although T4 makes up about 90% of the TH 
secreted by the thyroid gland, T3 is the more biologically active hormone (10 times more 
so than T4) and has a higher affinity for nuclear receptors. T4 is more likely to be bound 
to proteins in the plasma like thyroxine-binding globulin (resulting in less “free” T4) – 
and when it does enter cells, it is immediately converted to the active hormone T3 
through deiodination (Nussey & Whitehead, 2001). Deiodinase enzymes, which alter TH 
activity by removing iodine molecules, are therefore crucial components of TH action. 
Deiodinases types 1 and 2 (D1, D2) convert T4 into the more active T3, while deiodinase 
type 3 (D3) converts T3 into the biologically inactive reverse T3 (rT3) (Nussey & 
Whitehead, 2001; Leach & Gould, 2015). D2 activity in glial cells, particularly 
astrocytes, provides most of the T3 needed for neuronal function (Leach & Gould, 2015).  
Thyroid hormone receptors (TRs) in the nuclei of target cells also play an 
important role in thyroid function. THs primarily exert their action through the binding of 
T3 to TRs, which bind to specific DNA sequences and initiate gene transcription. Recent 
work has found that thyroid hormone receptors can additionally act without THs present, 
mainly through inhibitory mechanisms that suppress gene expression (Buras, Battle, 
Landers, Nguyen, & Vasudevan, 2013; Venero et al., 2005).   
Finally, thyroid hormone transporters – such as the monocarboxylate transporters 
8 and 10 (MCT8, MCT10) and the organic anion-transporting polypeptides (OATP) – are 
proteins that allow THs to cross the membranes into target cells (Raymaekers & Darras, 
2017). MCT8 is especially important for transport of TH through the blood-brain barrier 




and CSF; in fact, MCT8 mutations in humans are associated with severe developmental 
delays and neurological damage (Bernal, 2005). One study found that D2 and MCT8 are 
both crucial for normal activity in the mouse cortex (cited in Leach & Gould, 2015), 
which highlights how these various enzymes and transporters are just as important to 
proper thyroid function as the THs themselves. 
 TH dysfunction. The importance of thyroid hormones can be demonstrated 
through the detrimental effects that result from their abnormal functioning. Too much TH 
synthesis and secretion leads to hyperthyroidism, characterized by symptoms like weight 
loss, fatigue, increased heart rate, and tremors. Too little leads to symptoms associated 
with hypothyroidism like weight gain, dry skin, hair loss, fatigue, low energy levels, and 
overall weakness (Nussey & Whitehead, 2001). 
Proper TH function is particularly essential during fetal and postnatal 
development, and deficiencies during critical time windows can cause permanent 
neuronal damage. For example, thyroid hormone dysfunction in pregnancy has been 
found to impact crucial processes like neurogenesis, cell migration, and axonal 
myelination in rats (Bernal, 2015). In humans, maternal iodine deficiency – which results 
in decreased TH production to the fetus – is associated with impairments like ADHD, 
decreased intelligence, and impaired mental and motor functioning (Morreale de Escobar, 
Obregon, & Escobar del Rey, 2004). Recent work suggests that THs influence 
development and neurogenesis in the adult brain as well, making adult-onset thyroid 
disorders of serious concern (Remaud, Gothie, Moryan-Dubois, & Demeneix, 2014; 
Leach & Gould, 2015). 




As described above, proper thyroid function involves multiple components. The 
stimulatory and inhibitory effects that TRH, TSH, T4, and T3 have on one another 
emphasizes how complex this system is, and abnormalities within the system could 
therefore have various underlying causes. This study focuses on hypothyroidism as a 
potential model of depression, but it should be noted that there are three main forms of 
the disorder. Primary, or overt hypothyroidism, involves having low concentrations of 
TH with an increased level of TSH. Thyroid tissue is thus stimulated by TSH, but 
complications in the thyroid gland (as well as antibodies against crucial elements of TH 
synthesis like TPO and thyroglobulin) result in fewer THs being synthesized and secreted 
(Nussey & Whitehead, 2001). Central hypothyroidism is characterized by low TH and 
TSH levels, wherein the gland is insufficiently stimulated due to defects in the pituitary 
(secondary hypothyroidism) or hypothalamus (tertiary hypothyroidism). Subclinical 
hypothyroidism (SCH) is considered to be milder, where TSH levels are elevated but 
serum T3 and T4 appear normal (Forman-Hoffman & Philibert, 2006). 
Thyroid dysfunction is a significant health problem worldwide, with one review 
estimating its prevalence in 10% of the total population (Leach & Gould, 2015). A report 
on its epidemiology found specific populations and regions to be differentially affected 
by thyroid disorders, with economic advancement and iodine nutrition being key 
determining factors (Taylor et al., 2018). Prevalence of overt hypothyroidism ranges from 
.2% to 5.3% in Europe, and 0.3% and 3.7% in the United States according to most large-
scale studies. This rate increases among individuals from 85 and 89 years of age, is 
approximately 10 times more prevalent in females, and does not include subclinical or 
other non-overt cases. Additionally, about one-third of the global population lives in 




iodine-deficient areas where incidence of thyroid dysfunction is expected to be 
significantly higher (Taylor et al., 2018). 
Associations between TH Function and MDD 
Like hypothyroidism, MDD is a multifaceted disorder involving multiple 
subtypes, symptomologies, and degrees of severity. According to the DSM-V, individuals 
must display at least one of the two main diagnostic criteria – depressed mood and 
decreased interest in once-enjoyable activities – in ways that are both persistent and 
detrimental to normal functioning. The remaining criteria include a broad range of 
symptoms, such as changes in sleep, appetite, and energy; recurrent negative thoughts or 
thoughts of suicide; and deficits relating to psychomotor and/or cognitive functions 
(American Psychiatric Association, 2013). Specific symptoms can thus differ greatly 
from patient to patient, as can the socio-environmental and genetic factors that influence 
them. 
The great complexity of both conditions is important to keep in mind while 
reviewing studies that examine their association, and it should also be noted that studies 
may differ in their operationalization of each. For example, TH concentrations can be 
measured in the plasma or CSF, and researchers can look at free or total levels. 
Depression can be measured via self-report scales (of which there are many), clinical 
interviews, or the mere existence of a past diagnosis. Studies in this literature also differ 
in when and where they were conducted; participant age, type, and sample size; and 
overall methodology and research design. 
Depressive symptoms in hypothyroid patients. The disturbances in mental 
health that accompany hypothyroidism, particularly depressive symptoms, are well 




known and widely accepted in the literature (Dayan & Panicker, 2013; Bathla, Singh, & 
Relan, 2016). A review by Boswell et al. (1997) found the prevalence of depression in 
hypothyroid patients to be near 50%, and Jain (1972) reported clinical depression in 40% 
in another hypothyroid sample. More current literature similarly reports high frequencies 
of depressive symptoms in hypothyroid patients, and the results are remarkably 
consistent. One study by Bathla et al. (2016) found that 60% and 63% of 100 hypothyroid 
patients reported some degree of depression or anxiety, respectively. Another by 
Chaudhary et al. (2014) reported that 63% of patients in their 100-patient sample had 
signs of depression as assessed by scores on the Hamilton Depression Rating Scale 
(HDRS). Demartini, Masu, Scarone, Pontiroli, and Gambini (2010) found an identical 
depression prevalence of 63% compared to 28% of euthyroid controls. Depressive 
symptoms were also found to be significantly more severe in patients with overt thyroid 
disorders compared to controls (measured with the HDRS) in a study by Gulseren et al. 
(2006), which followed 140 participants with overt or subclinical dysfunction. Their 
additional finding of significantly lower quality of life (QOL) scores among patients was 
not surprising, given that patient QOL scores were compared with those of healthy 
participants. Still, the authors found it telling that depression and QOL scores both 
improved significantly over the course of treatment despite the fact that thyroid treatment 
did not include antidepressant drugs. These data suggest that restoration of TH levels can 
improve concomitant psychological symptoms.  
Some authors question the association between thyroid function and depression 
based on large-scale studies with negative findings. One study of 30,589 participants in 
Norway, for example, failed to find a definitive association between thyroid dysfunction 




and scores on the Hospital Anxiety and Depression Scale (Engum, Bjoro, Mykletun, & 
Dahl, 2002). In fact, they reported that a subset of subjects with overt hypothyroidism, as 
determined by blood tests of T4 and TSH, had significantly lower risks of both 
depression and anxiety. Although higher depression rates were found in subjects with a 
self-reported thyroid disorder, the authors found that the majority of these subjects 
actually had normal levels of TH. They suggested that patients with self-knowledge of 
thyroid dysfunction might be more inclined to report symptoms of depression in a type of 
“labeling effect.” Another study that followed 606 elderly patients at risk for 
cardiovascular disease (aged 70-82) found no relationships between thyroid status and 
self-reported depressive symptoms, either at baseline or 3 years later (Blum et al., 2016). 
It is possible that factors like age affect relationships between mood and thyroid 
dysfunction, which is supported by work from Zhao, Chen, Zhao, and Shan (2018). Their 
meta-analysis of 14 studies examining associations between subclinical hypothyroidism 
and depression failed to find significant connections between the two, but there was a 
significant correlation when only studies with younger subjects were analyzed (mean 
subject age < 60). This finding could potentially help explain the negative results by 
Blum et al. (2016) in their large geriatric population.  
The prevalence of depression among hypothyroid patients is thus inconsistent 
across studies and seems to depend on a number of factors. Still, patterns in the literature 
do support their association. The following section examines the opposite end of this 
relationship – thyroid dysfunction among patients with MDD. 
Thyroid dysfunction in MDD. There is widespread evidence that depressed 
patients – especially those who are resistant to traditional antidepressant treatment – have 




a higher prevalence of thyroid dysfunction than the general population. One meta-
analysis reported that 52% of patients with treatment-refractory depression exhibited 
subclinical hypothyroidism across 6 studies, compared with 8-17% of patients with 
nonrefractory depression and 5% of healthy controls (Sintzel, Mallaret, & Bougerol, 
2004). An analysis of 1,000,000 random subjects from a National Health Research 
Institute database also found a higher incidence of primary or secondary hypothyroidism 
among MDD patients than the general population (0.4% compared to 0.13%), and a 
higher incidence of hyperthyroidism as well (0.72% compared to 0.32%; Wu, Chien, Lin, 
Chou, & Chou, 2013). Studies have additionally found abnormal TH concentrations in 
MDD patients, with the most consistent findings being that depressed patients have 
decreased TSH response to TRH as well as increased levels of T4, rT3, and TRH 
(reviewed in Nemeroff & Evans, 1989; Bahls & Carvalho, 2004; Hage & Azar, 2012). 
TSH. TH response to TRH is normally measured with the TRH stimulation test, 
where TRH is administered intravenously and blood samples are taken at several time 
points to measure the ensuing TSH levels. Recall that TRH will normally stimulate 
release of TSH from the anterior pituitary, which subsequently stimulates TH production 
and release. An early study by Prange et al. found that 25% of MDD patients showed a 
decreased TSH response despite having normal baseline TSH and TH levels, and a 
comprehensive review of 45 studies confirmed this finding (Loosen, Garbutt, & Prange, 
1987). Other groups have come to the opposite conclusion, however. One review 
reported increased TSH response in 10-17% of depressed patients (Nemeroff, 1989), and 
another study found the increase in an astounding 60% of cases (Gold, Pottash, & Extein, 
1982). 




Results of studies that simply measure TSH concentrations in the bloodstream 
(without administering TRH beforehand) are similarly mixed. Cleare, McGregor, and 
O’Kearne (1995), for example, found that hypothyroid patients with clinical depression 
had significantly higher TSH levels than those who were non-depressed. These 
concentrations correlated positively with self-reported depression scores. In contrast, 
depressed inpatients in a study by Rao et al. (1996) had lower plasmatic TSH than 
controls. Saxena, Singh, Srivastava, and Siddiqui (2000) reported lower TSH levels in 
mildly depressed patients and higher TSH levels in severely depressed patients when 
compared to a control group, although all values were considered to be within the normal 
range. It is thus possible that TSH expression in MDD varies among patients with 
different levels or subtypes of the disorder. 
Another interesting line of research found that MDD patients lack the nightly 
surge in serum TSH levels that occurs in healthy subjects (Bahls & Carvalho, 2004). This 
nightly TSH increase has been found to return to normal once patients have recovered. 
Hormone concentration differences relating to the time of day they are measured could be 
another potential explanation for inconsistent findings. 
T4. Depression is also commonly associated with increased total and plasma T4 
levels, a finding that reportedly applies to 20-30% of MDD patients (Bahls & Carvalho, 
2004). Correlations have been found between increased T4 and depression severity, and 
T4 levels have been found to decrease as the disorder remits. One study found 
significantly elevated T4 in the CSF of 12 depressed patients, which normalized after 
successful electroconvulsive treatment (Kirkegaard & Farber, 1991). Another found that 
both total and free T4 levels significantly decreased after 4 weeks of antidepressant 




treatment in a 21-patient sample (Rao et al., 1996). Berent, Zboralski, Orzzechowska, and 
Galecki (2013) similarly found significant positive relationships between free T4 
concentrations and depression severity in 44 inpatients (as measured by the HDRS upon 
admission). Interestingly, both Rao et al. (1996) and Berent et al. (2013) also found that 
higher baseline plasma T3 and T4 levels were associated with greater reported clinical 
improvement on depression rating scales. Rao et al. (1996) suggested that higher TH 
levels might compensate for the decrease in THs elicited by antidepressant treatment. 
Berent et al. (2013) speculated that higher T4 levels could indirectly improve symptoms 
by being a source for more T3.  
One theory explaining the increased T4 levels in depression is that the increase 
results from inflated TSH secretion (and therefore increased stimulation of the thyroid 
and TH synthesis). This idea was suggested by Kirkegaard, Korner, and Faber (1990) in a 
turnover study using radiolabeled T4, where a small sample of depressed patients showed 
significantly increased production of T4 compared to controls. One would expect TSH 
levels to then be decreased in these depressed patients due to the negative feedback loop, 
but serum TSH levels in both groups were the same. Furthermore, depressed patients had 
higher serum TSH levels when compared to a separate group with identical levels of T4 
production (these were nondepressed patients taking thyroxine for a hypothyroid 
condition). This supports the hypothesis that inflated TSH concentrations in depression 
could precede (and thus result in) the increased levels of T4.  
Another possibility is that increased cortisol, which is heavily implicated in the 
disorder, could lead to inhibition of the D2 enzyme that converts T4 to T3. Recall that T3 
is the biologically active thyroid hormone that binds to nuclear receptors and carries out 




specific functions. In the cerebral cortex, 80% of T3 used is not secreted by the thyroid 
gland directly, but rather produced through local deiodination of T4 (Hage & Azar, 
2012). Inhibition of D2 would lead T4 to be primarily converted to rT3, the hormone’s 
inactive form, through the D3 enzyme instead. This idea is supported by the increased 
levels of rT3 commonly found in the CSF of depressed patients (Hage & Azar, 2012). 
Depressed patients were also found to have decreased CSF concentrations of 
transthyretin, a protein important for T4 transport to the brain. Levels were lowest among 
patients with greater symptom severity (Sintzel, Mallaret, & Bougerol, 2004). This 
suggests that even if T4 concentrations are found to be normal or increased in the plasma, 
there could be less TH available in the brain for neuronal use. 
TRH. Several groups have also reported increased TRH levels in the CSF of 
depressed patients, with one study reporting a nearly threefold increase in MDD patients 
compared to controls (Nemeroff & Evans, 1989). Hage and Azar (2012) suggested that 
the T4 increase could result from increased activation of TRH-producing neurons in the 
hypothalamus, based on the finding that tricyclic antidepressants and SSRI’s have both 
been found to reduce TRH concentration in rats in a dose-dependent manner. 
Antidepressants also reduced TRH response to glucocorticoid stimulation, which 
suggests that the rise in cortisol associated with depression could result in increased 
stimulation of TRH. However, studies looking for increased TRH in the CSF of 
depressed patients have yielded negative findings as well (Roy, Wolkowitz, Bissette, & 
Nemeroff, 1994). 
Summary. In sum, although there are some inconclusive findings in the literature, 
there is also overwhelming evidence associating depression with some form of thyroid 




dysfunction. It should be noted that “thyroid dysfunction” in this context does not 
necessarily refer to formal diagnoses of thyroid disorders, as even subtle changes in TH 
levels can have profound impacts on mood (Bathla, Singh, & Relan, 2016). In many of 
the studies described below, for instance, depressed patients showed hormone levels that 
are significantly different from controls but still within the “normal” euthyroid range (e.g. 
Rao et al., 1996; Saxena, Singh, Srivastava, and Siddiqui, 2000; Hage & Azar, 2012). 
Authors have discussed the possibility of “brain hypothyroidism in the setting of systemic 
euthyroidism” (Hage & Azar, 2012), wherein lower TH availability in the brain might to 
unnoticed if hormone levels in the peripheral organs are normal. Findings of increased 
CSF levels of rT3 and decreased CSF levels of the T4 transporter transthyretin, discussed 
above, both provide support for this idea. A brain-specific TH deficiency would also 
explain why some larger-scale population studies fail to find a definitive link between 
hypothyroidism and depression diagnoses (e.g. Engum et al., 2002; Blum et al., 2016).  
Forman-Hoffman and Philibert (2006) conducted a large-scale study that was 
particularly interesting in that none of the 6,869 participants they included had any 
previously documented thyroid disorders. Depressive symptoms were assessed with self-
reports and clinical interviews, and serum T4 and TSH levels were measured. In men, 
current depressive symptoms in these euthyroid subjects were significantly associated 
with lower TSH. T4 was also strongly associated with depressive symptoms in both 
males and females, which is supported by evidence reviewed above. Interestingly, TH 
abnormality was associated with current depressive symptoms but not lifetime history of 
the disorder. This is consistent with numerous reports that TH levels normalize after 
successful antidepressant treatment. 




This study, like many other reported findings in this literature, demonstrates how 
TH abnormalities can exist in depression without being attributed to an overt thyroid 
disease. This also underscores the important point that although TH disorders and MDD 
share many common mechanisms, the two conditions remain qualitatively different. The 
DSM-V accordingly states that a diagnosis of depression may be inappropriate if changes 
in mood are thought to be a result of medical conditions like hypothyroidism (American 
Psychiatric Association, 2013). Along these lines, TH treatment – further reviewed in the 
following section – has been found to show antidepressant-like effects on MDD patients 
who had no diagnosed thyroid-related illness. 
Antidepressant properties of thyroid hormones. One review reported that 
about 30% of depressed patients fail to respond to antidepressant treatment, and 67% of 
these treatment-resistant patients benefit from the addition of thyroid hormones (Henley 
& Koehnle, 1997). These authors argued that because traditional antidepressants take 
weeks to show clinical benefits, they likely act on second messenger systems that trigger 
the intracellular signals responsible for the treatment effects. Thyroid hormones act on a 
synaptic level and directly influence gene expression, so their addition could theoretically 
strengthen and speed up the process. Clinical studies have supported this idea, such as an 
early study by Goodwin, Prange, Post, Muscettola, and Lipton (1981). A sample of 12 
MDD patients with no signs of TH dysfunction showed no response to tricyclic 
antidepressants (TCAs) after a 4-week trial, so T3 was added to their medication 
treatment. Depression ratings were assessed twice a day on the Bunney-Hamburg scale. 
Nine of the 12 patients showed significant symptom reductions – an effect that was 
detected within the first three days of T3 treatment. Another meta-analysis found that in 




five out of six clinical studies, addition of T3 to TCAs was more effective than addition 
of placebo with a weighted effect size of 0.58 (Altshuler et al., 2001).  
Significant effects of T3 augmentation have not always been found, however. A 
meta-analysis of randomized, double-blind trials by Papakostas et al. (2009) found no 
added benefit of T3 to SSRIs when compared to SSRI treatment alone. Another by 
Cooper-Kazaz and Lerer (2008) reviewed three different studies where T3 was added 
with SSRIs before the start of treatment. One study found T3 to have a strong and 
positive effect on treatment, one found no benefit, and one found a slight trend that was 
ultimately insignificant. Additionally, a STAR*D report (part of a larger collaborative 
antidepressant study) did find that addition of T3 was more effective than lithium in 
patients resistant to the SSRI citalopram (25% vs. 16% achieved remission), but this was 
also an insignificant trend (Nierenberg et al., 2006). It has been suggested that 
combination of T3 with antidepressants – SSRIs in particular – is most effective for a 
specific subgroup of patients with atypical depression. The meta-analyses mentioned 
above are limited in that the studies reviewed differ in terms of their specific patient 
population. In addition, the T3-SSRI combination has been found effective in patients 
with a D1 enzyme polymorphism that limits T4 deiodination to T3 in the bloodstream 
(Papakostas et al., 2009).  
Studies investigating treatment of depression with thyroxine (T4) have yielded 
similarly mixed results. One group found addition of T4 to antidepressant treatment 
significantly reduced HRSD scores in MDD patients who had been treatment-resistant to 
at least two chemically different medications (Bauer, Hellweg, Graf, & Baumgartner, 
1998). However, thyroxine was found ineffective as monotherapy for comorbid SCH and 




MDD patients (i.e. without additional antidepressant treatment) which suggests that T4 
cannot substitute for traditional antidepressants (Kalra & Balhara, 2014). In their pooled 
analysis of 6 papers and 266 subjects, Loh, Lim, Yee, and Loh (2019) also found that in 
patients with both SCH and depression, treatment of SCH with T4 was not associated 
with improvement in depressive symptoms. In general, T4 is not thought to be as 
effective as T3 for treatment in MDD patients (Bahls & Carvalho, 2004; Zhao, Chen, 
Zhao, & Shan, 2018). This is consistent with the hypothesis that impaired conversion of 
T4 to T3 could be a driving mechanism behind depressive symptoms.  
Antidepressant effects of thyroid hormones have also been studied in animal 
models, and treatment has often successfully reduced hypothyroid-induced symptoms of 
depression. Further literature on this subject is reviewed below. 
Depressive symptoms and thyroid function in animal models. Given that the 
current study examined depressive symptoms in hypothyroid mice, past experiments in 
animal models are especially relevant. There are several studies that support the idea of 
using hypothyroid animals as an MDD model based on the behavioral effects observed. 
In one, subclinical hypothyroidism was induced in rats by surgically removing one lobe 
of the thyroid gland. These rats showed increased depression-like behavior in two 
common behavioral measures with predictive validity for antidepressant-like drug 
effects: the tail suspension test and forced swim paradigm (Ge, Peng, Qi, Chen, & Zhou, 
2013). Interestingly, induced hypothyroidism did not affect behavior in the sucrose 
preference test – the measure used for depression in the current study. 
Reductions in sucrose preference have been reported in other hypothyroid models, 
however, including a study by Rivlin, Osnos, Rosenthal, and Henkin (1997) that rendered 




rats hypothyroid through administration of radioactive iodine. Control rats consistently 
preferred water sweetened with sucrose to regular water, but sucrose preference in 
hypothyroid rats was significantly lower (below 50%). This is commonly used as a 
measure of anhedonia, a characteristic symptom of major depression. Hypothyroid rats 
additionally had an increased preference for salty and bitter water (water with NaCl and 
quinine sulfate, respectively); but the hypothyroid preference for quinine sulfate was 
successfully reversed after treatment with thyroxine. 
Further evidence supporting depressive-like effects of hypothyroidism comes 
from Ge, Xu, Qin, Cheng, & Chen (2016), who induced subclinical hypothyroidism in 
rats through hemithyroid electocauterization. Untreated hypothyroid rats had significantly 
lower sucrose preference, significantly more anxiety-like behavior in an open field test 
(decreased locomotion and rearing activity), and significantly more depressive behavior 
in the forced swim paradigm (increased immobility). Separate groups of rats were treated 
with either thyroxine or resveratrol, which has been found to induce antidepressant-like 
effects in chronic stress models. Both treatments reversed all of the depressed and 
anxious behaviors, as well as the increased plasma TSH levels induced by subclinical 
hypothyroidism. 
Surgically thyroidectomized rats also displayed more immobility in the forced 
swim test in a study by Kulikov, Torresani, and Jeanningros (1997). Thyroidectomized 
rats on a low-iodine diet – referred to as having severe hypothyroidism – had 90% 
decreased immobility compared to controls. Rats with mild hypothyroidism (intact 
thyroids but low-iodine diets) also displayed significantly more immobility, with an 
increase of 60%. 




While the studies above involved lesion models of hypothyroidism – including 
surgical, electrical, and radioactive removals of the thyroid – other groups have utilized 
genetic models. Rodents in these studies are genetically bred to lack the thyroid receptor 
alpha 1, which binds to T3 and is vital for TH expression. One study found that mice 
lacking this receptor exhibited significantly less exploratory behavior and more freezing 
than control mice in an open field test (Guadano-Ferraz et al., 2003). Another found that 
mutant hypothyroid mice displayed significantly more depressed behavior in a learned 
helplessness paradigm, as well as significantly more anxiety in startle response and light-
dark box tests (Pillhatsch et al., 2010). These effects were reduced for hypothyroid mice 
treated with T3, demonstrating that the thyroid hormone could have antidepressant 
properties in animal models. When control mice were treated with T3, however, they 
displayed more depressive behavior and reduced locomotion. The authors suggested that 
T3 treatment in the absence of hypothyroidism could have resulted in a hyperthyroid 
state, explaining the depressive-like effects. 
In another study, Wilcoxon, Nadolski, Samarut, Chassande, and Redei (2007) put 
mutant and control mice on hypothyroid, hyperthyroid, or euthyroid diets. As a group, 
mice lacking thyroid receptor alpha exhibited more depressive behavior than controls in 
the forced swim test. The hypothyroid diet increased this effect on mutant mice, but it 
had the opposite effect on controls. TH receptor deletion was also associated with spatial 
learning and memory deficits in the Morris Water Maze – an effect that was also 
exaggerated by the hypothyroid diet. The associations between hypothyroidism and 
related cognitive deficits are further reviewed in a separate section below. 




The current study used a chemical hypothyroid model by adding propylthiouracil 
(PTU) to the animal diets. This compound induces hypothyroidism by blocking the 
effects of TPO and inhibiting TH synthesis. Yu, Tang, Feng, and Cheng (2014) found 
that rats given this treatment had decreased body weight, decreased locomotor and 
rearing activity in an open field test, and decreased sucrose preference to regular drinking 
water. The degree of sucrose preference reduction additionally correlated with reduced 
glucose metabolism in the caudate putamen and nucleus accumbens.  
Interestingly, groups have also reported findings that are nearly opposite to those 
reported above. For instance, Yu et al. (2015) created hypo- and hyperthyroid models of 
rats using radioactive iodine or levothyroxine as part of their daily diet. When tested in 
the forced swim paradigm, hypo- and hyperthyroid rats both showed significantly less 
depressive behavior than controls. Hypothyroid rats were also significantly less depressed 
than the hyperthyroid group. In addition, hypothyroid rats showed an increased 
preference for sucrose – a response indicating less depression – and decreased anxiety 
compared to both hyperthyroid and normal rats. Treating hypothyroid animals with T4 
before testing actually increased depression- and anxiety-like behaviors, which further 
suggests that hypothyroidism had an antidepressant-like effect in this particular study. 
Mechanisms Implicated in both MDD and TH Dysfunction 
The significant limitations of current antidepressant drugs, such as low remission 
rates and delayed onset of action, have inspired a line of research devoted to uncovering 
the “next generation” of antidepressant treatment (e.g. Machado-Vieira et al., 2008; 
Murrough, 2012; van Calker, Serchov, Normann, & Biber, 2018). The mechanisms 
behind current antidepressants are largely based on the monoamine hypothesis, which 




proposes that depression stems from depleted concentrations of monoamines like 
serotonin, norepinephrine, and dopamine (Hillhouse & Porter, 2015). In the late 1950s, 
the drug iproniazid – originally developed for treating tuberculosis – was found to also 
significantly reduce depressive symptoms after several weeks of treatment. Iproniazid is 
an inhibitor of the enzyme monoamine oxidase (MAO), which is responsible for the 
breakdown of monoamines in the presynaptic terminal. The classes of antidepressants 
developed since then (e.g. tricyclic antidepressants [TCAs], selective serotonin reuptake 
inhibitors [SSRIs], and serotonin norepinephrine reuptake inhibitors [SNRIs]) similarly 
work by increasing concentrations of serotonin and/or norepinephrine in the synaptic 
cleft though differing mechanisms of action. However, the late onset of therapeutic 
effects suggests that monoamines might work indirectly by modulating additional 
intracellular signaling pathways that are more directly responsible for alleviating 
symptoms (Hillhouse & Porter, 2015).  
 Although most drug treatments have remained contingent on this 50-year-old 
hypothesis, research on the underpinnings of the disorder has actually come quite far. 
Notable work that has been done on MDD includes identifying specific brain areas 
implicated in its pathology, studying how MDD impacts normal neurogenesis, and 
investigating the role of glutamatergic neurotransmission.  Furthermore, work examining 
the rapid antidepressant effects of ketamine has revealed other critical components like 
AMPA and NMDA receptors, glial astrocytes, and synaptic plasticity. Achieving a “next 
generation” of antidepressants will require an advanced understanding of the biological 
mechanisms behind MDD – none of which occur in isolation. Given the well-
documented relationships between depression and thyroid function, as well as the critical 




role of TH on broad aspects of cell metabolism, it is of great relevance to examine the 
roles of TH in various MDD-related processes. The review below will demonstrate how 
the thyroid system and MDD share many biological processes, ultimately supporting the 
use of hypothyroidism in an MDD model. 
 Monoamines. The hypothesis that depression stems from deficiencies in the 
serotonin (5-HT), norepinephrine (NE), and/or dopamine (DA) neurotransmitter systems 
is one of the most well-known theories of the disorder. Despite significant limitations and 
delayed treatment effects, drugs that increase these neurotransmitter levels have 
undoubtedly helped MDD patients achieve remission for over 50 years. It is thus widely 
acknowledged that while monoaminergic systems are likely not the primary target of 
antidepressant action, they nonetheless likely play a major role in depression’s pathology 
(Maeng & Zarate Jr., 2007). As supporting evidence, changes in serotonergic 
neurotransmission are associated with response to antidepressants; unmedicated MDD 
patients have reduced 5-HT metabolite levels in the CSF; and MDD patients show 
reduced 5-HT transporter availability in imaging studies (Bauer, Heinz, & Whybrow, 
2002). Thus, close relationships found between thyroid hormones and monoamine 
activity supports the use of hypothyroidism in a depression model. 
Cleare, McGregor, and O’Kearne (1995) found that compared to controls, 
hypothyroid patients had reduced levels of central serotonin (indexed by measuring 
serotonin-mediated responses of cortisol to dexfenfluramine). Reduced 5-HT responsivity 
was also associated with higher self-rated depression scores as well as higher levels of 
TSH. The majority of research in this area similarly reports reduced 5-HT response in 
hypothyroid patients that reverses with TH treatment, and this finding has been heavily 




replicated and reviewed (Bauer, Heinz, & Whybrow, 2002; Bahls & Carvalho, 2004; 
Correa Santos et al., 2012).   
In rats, neonatal hypothyroidism has been associated with reduced concentrations 
of NE, DA, and 5-HT – as well as decreased activity of their rate-limiting enzymes, 
tyrosine and tryptophan hydroxylase (Singhal, Rastogi, & Hrdina, 1975). This study also 
found the thyroid-monoamine relationship to be time-dependent, as changes in 
monoamine metabolism were reduced when hypothyroidism was induced later in life (20 
days after birth). Treatment of hypothyroidism with T3 was also more effective in 
reversing its effects when it was introduced earlier. In a similar study, induced 
hypothyroidism at birth inhibited the normal developmental increases of NE and its 
synthesizing enzyme (activity was delayed by 34% and 31%, respectively). Rats treated 
with T3 early in life showed reduced neurochemical changes, while treatment later in life 
did not reverse the effects significantly (Rastogi & Singhal, 1974). The authors postulated 
that thyroid hormones might have to be present during a critical period for normal 
patterns of NE development. Studies of adult hypothyroid rats found reduced cortical 5-
HT concentrations and reduced whole-brain concentrations of the serotonin precursor 5-
HTP (Bauer, Heinz, & Whybrow, 2002). 
 Reverse effects have been found in hyperthyroid models. For example, one study 
found that experimentally-induced hyperthyroid rats had nearly 3 times more blood 
serotonin levels than controls, which decreased after a 3-week recovery period (Noll, 
Goke, Willemer, Richter, & Arnold, 1998). Another study similarly reported increased 
blood 5-HT levels in human hyperthyroid patients compared to controls, which were 
mitigated after three months of thyroid treatment (Upadhyaya, Argrawal, Dubey, & 




Udepa, 1992). This study also reported strong correlations between serotonin levels and 
T3 concentrations, providing further evidence of their relationship.  
In addition, components of the HPT axis have been found to be affected by 
traditional antidepressant treatment. One study with rats found that after 2 weeks on the 
tricyclic antidepressant desipramine, D2 increased in various brain areas commonly 
implicated in MDD including the frontal cortex and amygdala (Campos-Barros et al., 
1994). Increased D2 results in more deiodination of T4 and, consequently, more T3 
available for neuronal use. Serum levels of T4 were also reduced after treatment, which is 
consistent with decreased T4 found in antidepressant-treated patients (e.g. Brandy & 
Anton, 1989). Another study (Baumgartner, Dubeyko, Campos-Barros, Eravci, & 
Meinhold, 1994) found similar D2 enhancement after 2 weeks of fluoxetine 
administration in rats. They also found decreased D3 activity in several limbic and 
cortical regions, which would lead to a rise in T3 concentrations. 
 Hypothyroid status therefore can decrease monoaminergic activity; and, likewise, 
increasing monoamine neurotransmission through traditional antidepressant treatment 
can enhance TH function. The following sections will review how thyroid status and 
mechanisms of depression could overlap in their relationship to the glutamatergic system. 
Glutamatergic receptors and the antidepressant effects of ketamine 
Overview of glutamatergic receptors. The finding that ketamine induced long-
lasting antidepressant effects in treatment-resistant MDD patients in a matter of hours 
(Berman et al., 2000) has been one of the most significant advances in modern 
antidepressant research. Because ketamine is a noncompetitive antagonist of the 
glutamate receptor N-methyl-D-asparate (NMDA), glutamate neurotransmission has 




taken on a central role in models of MDD pathology. Glutamate is regarded as the 
primary excitatory neurotransmitter in the nervous system, with significant roles in 
learning, cognitive function, and cellular plasticity. It acts by binding to various receptor 
types on pre- and post-synaptic neurons; as well as astrocytes, which convert glutamate to 
glutamine, which pre-synaptic cells use for glutamate synthesis (Hillhouse & Porter, 
2015). NMDA and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors are the two most implicated in ketamine’s antidepressant-like actions. 
NMDA and AMPA are both ionotropic glutamate receptors. As ion channels, they 
depolarize the membrane potential of neurons which consequently activates signaling 
cascades with the cell (Machado-Vieira et al., 2009). The mechanical differences between 
NMDA and AMPA receptors reflect their differing roles and functions within the 
glutamatergic system. NMDA receptors are made of several types of NR subunits – 
specifically GluN1, GluN2A-D, and GluN3A-B. The amino acid glycine has binding 
sites on NR1, while glutamate binds to the various NR2 subunit types. In order for 
NMDA receptors to function, glycine and glutamate must both be bound to their 
respective subunits as co-agonists. NMDA action also requires that magnesium ions, 
which block NMDA channels, are removed through depolarization of the membrane by 
influx of sodium ions. AMPA receptors can achieve this depolarization to remove the 
magnesium ion blockade, making NMDA receptor action dependent on AMPA receptor 
stimulation (Maeng & Zarate, 2007; Hillhouse & Porter, 2015). AMPA receptors, on the 
other hand, are comprised of the subunits GluR1 – GluR4. Because they do not require 
co-agonist action or blockade removal, AMPA receptors are primarily responsible for the 
rapid and early excitatory synaptic response to glutamate (Machado-Vieira et al., 2009). 




NMDA receptors are associated with longer-term synaptic changes, such as long-term 
potentiation (LTP) implicated in processes of learning and memory (Zarif, Petit-Paitel, 
Heurteaux, Chabry, & Guyon, 2016). Unlike AMPA channels, NMDA channels also 
allow for the influx of calcium ions which are crucial for initiating various signaling 
cascades (Hillhouse & Porter, 2015).  
Ketamine studies, as well as the ensuing lines of research they inspired, have 
demonstrated that these glutamatergic receptors are closely related to symptoms of 
depression and may be implicated in its pathology. Associations have also been 
consistently found between AMPA receptors, NMDA receptors, and thyroid function. 
Evidence of these relationships raises the exciting possibility that TH could mediate 
depressive actions through its role in the glutamatergic system. 
Antidepressant actions of ketamine. The definitive mechanisms behind 
ketamine’s rapid antidepressant effects are still unclear. Despite being a noncompetitive 
NMDA receptor antagonist, ketamine administration is associated with increased 
glutamatergic activity; for instance, its administration was found to increase overall 
glutamatergic neurotransmission in the prefrontal cortex in healthy volunteers 
(Aleksandrova et al., 2017). One popular hypothesis is that ketamine could thus 
preferentially act on NMDARs located on inhibitory GABAergic interneurons. Blocking 
inhibition of excitatory neurons would result in a surge of glutamate transmission, 
leading to rapid synaptogenesis (Machado-Vieira et al., 2010; Duman & Aghajanian, 
2015; Aleksandrova et al., 2017). As support for this hypothesis, ketamine has been 
found to have a higher affinity for the NR2D subunits which are particularly concentrated 
in inhibitory interneurons in the forebrain (Zanos & Gould, 2018). 




On the contrary, evidence also suggests that NMDA antagonism might not be the 
primary mechanism of antidepressant action. Other NMDA antagonists such as 
dizocilpine (MK-801) have demonstrated antidepressant-like effects similar to that of 
ketamine (Machado-Vieira et al., 2010), but some researchers argue that their weaker and 
shorter-lasting results suggest that other factors could primarily modulate the therapeutic 
effects (Aleksandrova et al., 2017). Ketamine notably increases the presynaptic release of 
glutamate (Moghaddam, Adams, Verma, & Daly, 1997); and because NMDA receptors 
are blocked before cell activation, the glutamate preferentially favors AMPA. Some have 
suggested that this increased glutamatergic activity of AMPA relative to NMDA 
receptors could be an underlying mechanism behind the ketamine’s effects (Maeng et al., 
2008; Machado-Vieira et al., 2009). 
In this regard, there is accumulating evidence that AMPA receptors could play a 
primary role in the antidepressant actions of ketamine. Multiple research groups have 
found that ketamine significantly reduced behavioral symptoms of depression in rodents; 
but when animals were first treated with the AMPAR antagonist 6-Nitro-2,3-dioxo-
1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), it was no longer effective 
as an antidepressant (e.g. Maeng et al, 2008; Li et al., 2010; Koike, Iijima, & Chaki, 
2011). Zhou et al. (2014) similarly found that inhibiting AMPA activity with NBQX 
weakened ketamine’s effects, but enhancing AMPA activity with an agonist increased 
them. Chronic treatment with TCA and SSRI antidepressants was associated with 
increased synaptic expression of AMPA subunits (Martinez-Turrillas, Frechilla, & Del 
Rio, 2002; Du et al., 2004), and injections of AMPA have even been found to elicit 
significant antidepressant-like effects on their own (Akinfiresoye & Tizabi, 2013). 




A notable study by Li et al. (2010) comprehensively illustrated how various 
signaling pathways and synaptic plasticity are implicated in the actions of ketamine. They 
demonstrated that the mammalian target of rapamycin (mTOR) pathway – which is 
critical in rapid cell signaling and synthesizing proteins for synaptic function – was 
activated by ketamine in the prefrontal cortex (PFC) of rats. Ketamine also induced a 
rapid increase in extracellular signal-regulated kinases (ERK) and protein kinase B (Akt) 
expression, both of which are involved in pathways critical in mTOR activation. 
Additional effects of ketamine included increased expression of postsynaptic proteins, 
increased spine density in the medial PFC, increased electrophysiological response to 5-
HT, and decreased depressive- and anxiety- like behaviors in three behavioral paradigms. 
Importantly, the mTOR pathway, ERK and Akt pathways, and activation of AMPA were 
all vital to the antidepressant response, as inhibition of any of them blocked all of these 
ketamine-induced effects. 
Ketamine studies have thus demonstrated the critical role of glutamate receptors 
AMPA and NMDA on mood, showing that NMDA inhibition and AMPA enhancement 
are both associated with reduced depressive behaviors. Findings that THs mediate 
glutamate receptor activity, as well as expression of their subunits, therefore support the 
hypothesis that thyroid function could be involved in the MDD pathology. Importantly, 
they also play important roles in synaptic plasticity and intracellular signaling cascades – 
which, as Li et al. (2010) exemplified, are needed for antidepressant effects to occur. 
Relationship between TH and glutamate receptors. Several studies have 
demonstrated the effects of TH on glutamate receptor activity as well as effects of 
glutamate receptors on TH levels. For example, Losi, Garzon, and Puia (2008) used 




electrophysiological recordings to measure the effect of TH on NMDA-dependent 
currents in cultured rat hippocampal neurons. Both T3 and T4 administration resulted in 
decreased NMDA activity, illustrated through the dose-dependent inhibition of NMDA-
evoked currents. This is consistent with findings of ketamine-induced NMDA receptor 
downregulation, and suggests that THs could have a ketamine-like effect on NMDA 
receptor activity.   
Another interesting study by Alva-Sanchez, Becerril, Anguiano, Aceves, and 
Pacheo-Rosado (2008) demonstrated that hippocampal damage in hypothyroid rats could 
“depend” on NMDA channel activation. Rats were administered either tap water 
(euthyroid) or water with methimazole (hypothyroid), and two additional groups of 
hypothyroid rats received daily injections of either ketamine or MK-801 (both of which 
are noncompetitive NMDA receptor antagonists). After four weeks of treatment, the 
hypothyroid group had significantly more neuronal damage and cell death in CA1, CA2, 
CA3, and CA4 regions compared to controls. Interestingly, administration of both 
ketamine and MK-801 prevented this hippocampal damage. NMDA receptor inhibitors 
thus had a neuroprotective effect on hippocampal cells; and although depressive-like 
behavior was not assessed in this study, there is abundant evidence linking depression to 
hippocampal atrophy (Duman, 2004). It is plausible given these findings that NMDA 
overstimulation could be associated with a depressive phenotype. One weakness of this 
design, however, is that both ketamine and MK-801 have produced antidepressant-like 
effects. It is thus unclear whether they prevented cell damage through NMDA 
antagonism or through another shared therapeutic mechanism.  




On the other hand, multiple reports have associated hypothyroidism with reduced 
expression and transcription of NMDA receptor subunits (primarily in the hippocampus). 
For example, Cortes et al. (2012) found that in hypothyroid mice, postsynaptic densities 
of hippocampal neurons showed reduced expression of NR1 and NR2A/B subunits. Lee, 
Brady, and Koenig (2003) similarly found reduced mRNA expression of the NR1 subunit 
in the hippocampal region of thyroidectomized rats. Both groups thought this might 
reflect an association between TH deficiency and reduced NMDA receptors in the 
hippocampus. These findings appear to contradict that of the ketamine literature, but they 
do support the widespread reports of learning and memory impairment associated with 
hypothyroidism (Lee, Brady, & Koenig, 2003) which depend on glutamatergic and 
NMDA-mediated activity. Additionally, they could provide support for the growing 
contention that NMDA receptor antagonism does not necessarily underlie the 
antidepressant effects of ketamine (e.g. Maeng et al., 2008; Machado-Vieira et al., 2009). 
Of note, Lee, Brady, and Koenig (2003) found reduced NR1 mRNA in the hippocampus 
only, with no difference to controls in the hypothalamus, cortex, or amygdala. They also 
found no effects of hypothyroidism on AMPA subunit mRNA. 
There are also findings suggesting that thyroid hormones are regulated by the 
glutamatergic system, which adds further complexity to their relationship. Arufe, Duran, 
Perez-Vences, and Alfonso (2002) investigated the effects of various glutamate receptor 
agonists and antagonists on levels of TH when administered into the third ventricle. 
Administration of MK-801 and CNQX – which are NMDA and AMPA receptor 
antagonists, respectively – lead to decreased TSH and TH levels in the serum. The 
AMPA agonists kainic and domoic acid lead to increased serum concentrations of TSH 




while CNQX blocked these effects. These results suggest that TH production and release 
could be upregulated by glutamate, particularly through AMPA receptors. Similarly, 
another study demonstrated that administration glutamate (L-glu), NMDA and the 
AMPA agonists kainic and domoic acid all increased serum levels of T3, T4, and TSH 
(Alfonso, Duran, & Arufe, 2000). The increase in TSH occurred within 5 minutes, while 
the TH level increase took about 30 minutes to take effect. The authors suggested that 
glutamatergic receptors could play a role in stimulating TH secretion, and the timeline 
seems to confirm a direct effect on TSH followed by consequent TH synthesis. 
 Long-term potentiation. Further support for a role of TH in glutamate 
neurotransmission comes from their reported involvement in LTP. LTP refers to the 
process of strengthening synaptic activity in response to external stimuli which leads to 
long-term structural changes in neuronal connections. In the literature, these long-term 
changes are widely accepted as cellular indicators of learning and memory (Gerges & 
Aldakhi, 2004; Alzoubi, Gerges, Aleisa, & Aldakhi, 2009). Synaptic responses are 
notably mediated by NMDA and AMPA receptors (e.g. Zarif et al., 2016), so TH 
involvement in this process supports the contention that thyroid function could regulate 
these glutamatergic receptors.   
Associations between TH and LTP are reported particularly in hippocampal 
regions. As a brief overview, there are two major hippocampal pathways implicated in 
studies of LTP. Action potentials are transmitted from the entorhinal cortex to the dentate 
gyrus via the performant pathway. Pyramidal neurons in the CA3 hippocampal region 
then transmit signals received from the dentate to cells in the CA1 region via Schaffer 
collateral synapses (Gerges & Aldakhi, 2004). LTP can be experimentally induced by 




applying high-frequency electrical stimulation to electrodes implanted in hippocampal 
tissue. Activity can then be operationalized by excitatory postsynaptic potentials (EPSPs) 
recorded from the postsynaptic (receiving) cells (Gerges & Aldakhi, 2004).  
Reviews of this subject convey a rich literature concluding that TH function is 
important for these processes (Leach & Gould, 2015). In one study, rats made 
hypothyroid through PTU administration at one week of age had significantly reduced 
LTP in CA1 compared to control rats – an effect seen after only 2 weeks of PTU 
treatment (Niemi, Slivinski, Audi, Rej, & Carpenter, 1996). Another found that 
thyroidectomized rats had significantly impaired LTP in the dentate gyrus which could 
not be reversed with 20 days of TH treatment (Fernandez-Lamo et al., 2009). In contrast, 
Gerges and Aldakhi (2004) reported no differences in LTP between thyroidectomized 
and control rats in the dentate gyrus. However, LTP in the CA1 hippocampal region of 
hypothyroid rats was found to be completely abolished.  
This experiment by Gerges and Aldakhi (2004) is particularly noteworthy in that 
they also reported reduced levels of phosphorylated ERK1 and ERK2 in the CA1 region 
of hypothyroid rats. These protein kinases are important regulators of cell growth and 
activate various functions through phosphorylation. Recall that Li et al. (2010) found that 
ketamine, in addition to inducing antidepressant-like effects in behavioral paradigms, 
enhanced ERK signaling in the prefrontal cortex. ERK inhibitors abolished ketamine’s 
antidepressant effects; as well as its activation of the mTOR pathway, which they found 
to be critical for ketamine’s actions. The fact that Gerges and Aldakhi (2004) found these 
reductions in the CA1 region, where LTP was found to be impaired – and not the dentate 
gyrus, where hypothyroidism did not affect LTP – indicates that these kinases could be 




implicated in the mechanisms by which TH regulate synaptic plasticity. Taken together 
with Li et al.’s (2010) findings, it is possible that they could also be implicated in TH 
regulation of depressive and anxiety-like behaviors. This contention is reasonable given 
that ERK’s function by inducing rapid signaling cascades within the cell. 
Further support for the role of cellular signaling molecules in the relationship 
between LTP and thyroid function comes from a later study out of the same lab (Alzoubi, 
Gerges, Aleisa, & Alkadhi, 2009). This study assessed learning and memory 
performance, LTP in area CA1, and immunoblot analyses of signaling molecules in three 
groups of rats: control rats, thyroidectomized rats, and thyroidectomized rats treated with 
T4. The radial arm water maze task consisted of learning, short-term memory, and long-
term memory phases. Hypothyroid rats were significantly impaired for all three 
measures, and T4 treatment prevented the impairment. Hypothyroidism similarly 
impaired L-LTP in CA1, which T4 treatment normalized as well. Finally, the team 
reported reduced levels of total and phosphorylated cyclic-AMP response element 
binding protein (CREB) in CA1 neurons – which promotes gene expression for many 
plasticity-related proteins – as well as reduced phosphorylated ERK1 and ERK2. Rats 
treated with T4 did not show either these reductions, suggesting that TH can restore these 
molecules to normal levels. Because the ratio of total to phosphorylated ERK1/2 was 
reduced in hypothyroid tissue, the authors suggested a specific effect of TH on 
phosphorylation processes.  
LTP has also been investigated in regard to MDD, and chronic stress models have 
shown LTP impairments similar to that of hypothyroidism. One review cited several 
early studies wherein stress-induced depression in rats was associated with reduced LTP 




in hippocampal area CA1 (Popoli, Gennarelli, & Racagni, 2002). In one study, Shors, 
Seib, Levine, and Thompson (1989) found that rats in an “escapable shock” group – that 
is, rats who were administered electric shocks with the option of escaping into another 
compartment – showed reduced LTP in CA1 compared to control rats. Rats in an 
“inescapable shock” group who were unable to avoid shock administration showed 
reductions that were even more significantly more pronounced. Thus, it is possible that 
different levels of depression or stress can affect the degree of synaptic impairment. 
Antidepressant treatment has been found to reverse these effects, implying that enhanced 
glutamatergic activity and synaptic strengthen is involved in antidepressant mechanisms. 
For example, Stewart and Reid (2000) found increased LTP in the dentate gyrus of rats 
following treatment with two common antidepressant treatments – the SSRI fluoxetine 
and electroconvulsive stimulation (ECS). While fluoxetine and ECS showed comparable 
effects on transmission in the dentate, only ECS was associated with significant 
impairments in a spatial memory task. These findings led them to argue that their shared 
effects on hippocampal plasticity were likely related to processes of mood rather than 
cognition. 
Glutamate uptake. Involvement of the thyroid system on glutamatergic 
neurotransmission can be further demonstrated through its role in glutamate uptake. 
Excessive stimulation of glutamate receptors can result in neurotoxic levels of 
extracellular glutamate, which is regulated by astrocytes through Excitatory Amino Acid 
Transporter 1 (EAAT1) in humans, GLT-1 and GLAST transporters in rodents (Mendes-
de-Aguiar et al., 2008). In rat cortical neuron cultures, TH administration was found to 
enhance cell viability in glutamate- and NMDA-induced toxicity experiments. High 




levels of glutamate decreased cell survival by 64% in control cultures, while TH-treated 
cultures had no significant loss (Losi, Garzon, & Puia, 2008). This neuroprotective 
response was demonstrated in T4, T3, and even rT3. In another study, Mendes-de-Aguiar 
(2008) cultured newborn rat neurons with either T3-treated or control astrocytes. Cultures 
with T3 treated astrocytes showed significantly increased glutamate uptake, significantly 
increased mRNA and protein expression of GLAST and GLT-1, and stronger neuronal 
resistance against glutamate-induced toxicity. In combination with their involvement in 
important signaling cascades, these findings support the notion that THs could have 
important roles in cell protection, growth, and function. Furthermore, multiple studies 
have additionally reported increased extracellular glutamate in response to stressors in 
animal depression models (Sanacora, Treccani, & Popoli, 2013). One could hypothesize 
that decreasing toxic levels of glutamate might be one way in which THs protect against 
a depressive response.   
Neurogenesis. Many groups are now looking at depression primarily as a 
disruption of synaptic plasticity and growth. There are exciting lines of research that 
support a “neurogenetic hypothesis of depression” (Remaud, Gothie, Morvan-Dubois, & 
Demeneix, 2014), but the links between mood disorders, cognitive deficits, and 
neurogenesis are just starting to be fully uncovered. In adult brains, new neurons continue 
to be generated in the subventricular zone (SVZ) and the subgranular zone (SGZ) in the 
dentate gyrus of the hippocampus. Briefly, neural stem cells in these areas divide to form 
progenitors, which generate neuroblasts (Remaud, et al., 2014). Literature suggests that 
the neuroblasts migrate into existing neural circuitry, where they eventually become 
mature, functioning neurons (Montero-Pedrazuela et al., 2006). While the exact 




functional purpose of neurogenesis is unclear, many hypothesize that it contributes to 
hippocampal function (Remaud et al., 2014) and there is evidence that it is implicated in 
learning, memory, and mood (Desouza et al., 2005).  
Studies have consistently shown impaired hippocampal neurogenesis in animal 
depression models, as well as restored neurogenesis after antidepressant treatment 
(Duman, 2004). Additionally, blocking hippocampal neurogenesis with irradiation 
exposure makes antidepressants ineffective – suggesting that this neuronal growth is 
necessary for antidepressant efficacy (Santarelli et al., 2003). There is ample evidence 
that neurogenesis is affected by thyroid status as well (e.g. Remaud et al., 2014), which 
underscores the thyroid’s contribution to synaptic plasticity and growth. Desouza et al. 
(2005) was one of the first groups to demonstrate a clear role of TH function in 
neurogenesis in rats and found that induced hypothyroidism significantly decreased cell 
survival and neuronal differentiation in the SGZ. Hypothyroid rats that were treated with 
daily injections of T3/T4 did not show these reductions, suggesting that increased TH 
prevented hypothyroid-induced damage.  
A study by Montero-Pedrazuela et al. (2006) demonstrated not only that THs are 
essential for normal neurogenesis in the SGZ, but also the that the hypothyroidism-
induced impairments were related to depressive symptoms among individual animals. 
Their experiment compared control rats, rats made hypothyroid through surgery and low-
iodine diets, and recovery rats who received a T3/T4 treatment after surgery. The number 
of proliferating cells in the dentate was reduced by 30% in hypothyroid animals, along 
with significant reductions in newborn neuroblasts and dendritic tree growth. 
Hypothyroidism did not affect behavior in an object recognition task; but it significantly 




increased depressive behavior in a forced-swim paradigm, with higher depression related 
to reduced proliferating cells. TH treatment reversed all behavioral and neurological 
impairments, and recovery rats even had significantly more proliferation than euthyroid 
controls.  It is unclear whether this increase was due to higher TH levels from the 
treatment, or whether it reflected a type of compensatory mechanism to recover from the 
thyroidectomy. 
Hippocampal atrophy. Research on hypothyroidism and depression has 
consistently found the hippocampus to be implicated in both conditions. The 
hippocampus is recognized for its involvement in memory encoding, consolidation, and 
storage, which all rely heavily on processes of synaptic strengthening (Taskin et al., 
2011). LTP and neurogenesis are also primarily mediated by the hippocampus, as 
reviewed above, which both have strong associations with thyroid function and MDD. 
With the goal of elucidating the mechanisms of depression as they relate to TH function, 
it is worth exploring their common implications in this area.  
Notably, the density of TH receptors is particularly high throughout the 
hippocampus. This indicates that the hippocampus an important target region for TH 
action in the brain, which is supported by TH involvement in neurogenesis, LTP, 
cognition, and other hippocampal-related processes (Cooke, Mullally, Correia, O’Mara, 
& Gibney, 2014). There are many documented effects of hypothyroidism on hippocampal 
cells; for example, hypothyroidism in adulthood is associated with decreased HC volume 
and weight, reduced differentiation and survival of granule cells in the dentate gyrus, and 
increased expression of apoptotic signaling molecules in CA3 neurons (Lee, Brady, & 
Koenig, 2003; Taskin et al., 2011; Cortes et al., 2012; Raymaekers & Darras, 2017). In 




addition, behavioral and cognitive impairments associated with TH deficits reportedly 
correlate with reduced synaptic plasticity in the hippocampus (Losi, Garzon, & Puia, 
2008). An early study by Madeira et al. (1992) found significant hippocampal volume 
reduction after hypothyroid treatment in rats – an effect found whether the treatment was 
induced at birth or adulthood, and whether its duration was acute or chronic. Cell volume 
was significantly reduced in the CA3 hippocampal region, while the CA1 region showed 
both reduced volume and cell number. The degree of CA1 atrophy was increased when 
hypothyroidism was chronic. Another study found that offspring of rats made 
hypothyroid during pregnancy had reduced hippocampal volume and a thinner granule 
cell layer in adulthood (Gilbert, Goodman, Gomez, Johnstone, and Ramos, 2017), 
suggesting that these effects can be irreversible in some cases.   
There is also a rich literature linking depression to cell loss and atrophy in the 
hippocampus (Duman, 2004). A variety of brain imaging studies, for example, have 
reported reduced hippocampal volume in MDD patients. It is possible that decreased 
volume could be an indicator of reduced neurogenesis, but there are likely other factors – 
like cell death, glia loss, and damage to existing neurons – that contribute to this finding 
(Duman, 2004). An MRI study found a significant negative correlation of -0.6 between 
the length of time that patients had been depressed and bilateral gray matter volume in 
the hippocampus (Sheline, Sanghavi, Mintun, & Gado, 1999). Like the results of Madeira 
et al. (1992) which found greater hippocampal volume reduction in chronic vs. acute 
hypothyroidism, these data suggest that neuronal loss is greater for patients with longer 
durations of the depressed state.   




Much of the ketamine literature is additionally focused on hippocampal regions. 
For example, Tizabi, Bhatti, Manaye, Das, and Akinfiresoye (2012) found that 
genetically depressed rats given a chronic dose of ketamine exhibited an approximate 
25% increase in hippocampal AMPA receptor density, which was associated with 
significant reductions in depressive-like behavior. Zhou et al. (2013) yielded similar 
results with an AMPA receptor potentiator, and additionally found increased mTOR and 
brain-derived neurotrophic factor (BDNF) in both the hippocampus and PFC. 
Furthermore, traditional antidepressants like desipramine and fluoxetine lead to increased 
mRNA expression of AMPA receptor subunits in hippocampal regions (Du et al., 2006). 
It has been suggested that associations between hippocampal structure and 
depression could be related to the stress response. Elevated cortisol resulting from stress 
can have neurotoxic effects on hippocampal neurons, which could potentially lead to 
decreased neurogenesis, synapse formation, and cell survival (Liu, Liu, Wang, Zhang, & 
Li, 2017). Impairments in the hypothalamic-pituitary-adrenal (HPA) axis have been noted 
in depressed patients, resulting in increased cortisol and glucocorticoid levels. 
Experimental glucocorticoid administration has been found to reduce hippocampal 
neurogenesis in adult animals, which suggests that elevated glucocorticoid levels in 
depression could similarly have damaging effects (Duman, 2004). Thyroid function has 
also been associated with stress in the literature, and studies have reported lower TH 
concentrations in rodents using multiple chronic stress paradigms (Guo et al., 2014). 
Close associations between stress, TH activity, depressed mood, and neuronal growth 
could be another way by which hypothyroidism and MDD are connected to one another.  
 




The Present Research 
 Although the relationship between depression and hypothyroidism is not clearly 
defined, it is apparent from the literature that they share a number of underlying 
processes. This study sought to better understand their connection by examining the 
effects of hypothyroidism on three different depression-related constructs. The behavioral 
measures that were utilized – the saccharin preference test, elevated plus maze, and 
object placement test – allowed for the examination of a broad range of symptoms within 
the hypothyroid model. Importantly, each of these measures has been found to 
successfully predict antidepressant efficacy in previous literature.  
 Behavioral measures. 
 Saccharin preference test. This behavioral test is a measure of anhedonia, which 
is a well-known symptom of MDD. The DSM-V describes anhedonia as decreased 
enjoyment toward stimuli or activities that were once found pleasurable (American 
Psychiatric Association, 2013), which has been operationalized in rodents as decreased 
preference for sweetened water. In this paradigm, animals are briefly deprived of water 
and then exposed to two water bottles: one with regular tap water, and one with 
sweetened water. Rodents have been found to consume significantly less sweetened water 
after depression is induced – an effect shown to be reversed after chronic antidepressant 
treatment (e.g. Willner, Towell, Sampson, Sophokleous, & Muscat, 1987).  
 Elevated plus maze (EPM). The EPM is commonly used in animal models as a 
validated measure of anxiety. This test has been able to successfully evaluate the 
anxiogenic and anxiolytic properties of specific compounds, as well as examine the brain 
areas and mechanisms related to anxiety (summarized in Walf & Frye, 2007). Assessing 




anxiety-like behaviors is vital for the validation of a depression model, considering the 
close association between the two constructs. In humans, anxiety is extremely prevalent 
among patients with MDD and there is a high level of comorbidity between the two 
diagnoses (Preisig, Merikangas, & Angst, 2001). Some researchers have even proposed 
that a more dimensional model of psychiatric disorders, using depression and anxiety as 
axes, would represent symptomology more accurately than the categorical diagnoses in 
the DSM (Goldberg, 1996). 
 To this end, researchers commonly include the EPM in tests of animal depression 
models; and correlations between validated depression- and anxiety-related behavioral 
measures have consistently been found (e.g. Ducottet & Belzung, 2005; Hinojosa et al., 
2006; Lee et al., 2007; Chiba et al., 2012; Mendez-David et al., 2017). This particular test 
operationalizes anxiety as the ratio of time spent in open versus closed sections of a 
maze. Mice are placed onto an elevated maze shaped like a plus sign, where two “arms” 
of the plus sign have walls (and are thus “closed”) while the other two are open. Rodents 
are thought to be conflicted between two innate characteristics: a fear of heights and 
open/unprotected spaces, and a desire to explore novel environments. Greater amounts of 
time spent inside the protected, closed arms relative to the open arms reflect higher levels 
of anxiety (Walf & Frye, 2007). In addition to correlating with depressive-like behaviors, 
scores on the EPM are also correlated with biological markers of depression like reduced 
glucocorticoid receptor expression in the prefrontal cortex (Chiba et al., 2012) and 
decreased serotonin expression in the hippocampus (Lee et al., 2007). Performance has 
also found to improve after treatment with certain antidepressants such as chronic 




administration of fluoxetine (Silva et al., 1999) and the AMPA receptor positive allosteric 
modulator S47445 (Mendez-David et al., 2017). 
 Object placement test (OP). The OP is a measure of spatial memory, which has 
been found to be significantly impaired in depressed patients (e.g. Porter, Gallagher, 
Thompson, & Young, 2003; Duman, 2004). Many studies have also reported decreased 
hippocampal volume in depressed patients compared to healthy controls, which is a brain 
area strongly implicated in spatial memory function (Sheline et al., 1999; Videbech & 
Ravnkilde, 2004). Briefly, rodents are first familiarized with two identical objects and 
one of them is moved to a new location in a subsequent testing session. Due to their 
natural preference for novel objects over familiar ones, normal animals should spend 
more time exploring the object in the new location. Contrary behavior is thought to 
reflect spatial memory impairment. Novel object preference in this test has been found to 
be significantly decreased in chronic stress models of depression (e.g. Bowman, 2005) 
while treatment with antidepressants, such as vortioxetine, can significantly reverse the 
effects (Li, Sanchez, & Gulinello, 2017). 
Hypotheses. It was hypothesized that mice made hypothyroid through 
administration of 6-propyl-2-thiouracil (PTU) would display more depressive-like 
behavior than euthyroid control mice on each of the behavioral tasks. They were 
specifically expected to show a reduced preference for saccharin in the saccharin 
preference task, a lower percentage of time spent in the open arms of the EPM, and a 
decreased preference for exploring novel objects in the OP test. Additionally, adding 
thyroxine (T4) to the PTU treatment was expected to reverse any hypothyroidism-
induced effects by restoring TH concentrations to a normal level.  






 All experimental procedures were approved by Montclair State University’s 
Institutional Animal Care and Use Committee (approval number 2018-047) and were 
consistent with the ethical guidelines set in the National Institute of Health’s Guide to the 
Care and Use of Laboratory Animals (2011). 
Materials and Measures 
 Animals. This study used male C57BL/6J mice for the hypothyroid model. Mice 
are commonly used in medical research and have been documented to be able to 
successfully perform cognitive and behavioral tasks. Rodents have also been found to 
resemble humans in terms of their genetic and behavioral characteristics, and symptoms 
of various human conditions have been successfully replicated in mouse models (Melina, 
2010). Male mice were used exclusively to avoid potential hormonal confounds related to 
the female estrous cycle (Beery & Zucker, 2010). 
Forty-five male C57BL/6J mice arrived at the university vivarium at 5 weeks of 
age (The Jackson Laboratory, Farmington, CT). Mice were housed 5 to a cage and 
maintained at a room temperature ranging from 65-75°F with 30-70% humidity. They 
were kept under a standard 12-hour light/dark cycle, lights on at 7:00 am, and given 
water ad libitum from a central water source. In accordance with IACUC guidelines, 
mice were left undisturbed for a one-week period to acclimate to the environment with 
free access to standard rodent chow (Laboratory Autoclavable Rodent Diet 5010; 
LabDiet, St. Louis, MO). During the following two weeks, mice were weighed and 




handled twice a week to habituate researcher interaction. They were also switched onto 
the study control diet (see below) until experimental treatments began. 
 Experimental treatments.   
6-propyl-2-thiouracil (PTU): PTU is an antithyroid compound that works by 
inhibiting function of thyroid peroxidase (TPO), a crucial enzyme implicated in thyroid 
hormone synthesis. Specifically, the drug blocks the oxidation of iodide ions and the 
iodination of tyrosine induced by TPO (Taurog, 1976), which are necessary for the 
production of T3 and T4. PTU is commonly administered to human patients to help lower 
the severely high thyroid hormone concentrations associated with hyperthyroidism and 
Graves’ disease (U.S. Food and Drug Administration, 2015). Administration of PTU has 
also successfully induced hypothyroidism in mice and rats in published experimental 
studies (e.g. Silva & Giusti-Paiva, 2014; Yu, Tang, Feng, & Chen, 2014; Armada-Dias, 
Carvalho, Breitenbach, Franci, & Moura, 2001). 
In the present study, PTU (Sigma-Aldrich, St. Louis, MO) was administered with 
food at a concentration of 0.5g per kg of rodent chow (0.05% of food weight). Table 1 
estimates the dosages of PTU based on the amount of food consumed. 
(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic 
acid (thyroxine): In humans, thyroxine is used to treat hypothyroidism and other thyroid 
hormone deficiencies (Vaidya, 2008). It is also secreted naturally by the thyroid gland 
along with its metabolite T3, and both induce metabolic effects by binding to thyroid 
hormone receptors in cells throughout the body. Experimental administration of 
thyroxine has been found to increase serum thyroid hormone levels in rodents (e.g. 
Kulikov & Zubkov, 2007; Zubkov, Kulikov, Naumenko, & Popova, 2009) as well as 




successfully reverse the behavioral and biological effects of induced hypothyroid states 
(e.g. Kulikov, Torresani, & Jeanningros, 1997; Armada-Dias et al., 2001). It was 
therefore expected that in the current study, administering thyroxine would help to 
normalize the thyroid hormone production inhibited by PTU.  
 Thyroxine (Sigma-Aldrich, St. Louis, MO) was administered through food at a 
concentration of 0.5 g/kg of chow (0.05% of food weight; see Table 1 for the estimated 
dosages). It was only administered with PTU, as the combination treatment was meant to 
provide a comparison group of euthyroid controls. In the present study, however, 
thyroxine administration did not produce this desired euthyroid effect. Mice in this 
condition began to show signs of hyperthyroidism around the third week of treatment, 
suggesting that the thyroxine dose used was higher than anticipated. The results section 
describes some of the unexpected effects resulting from thyroxine treatment, such as 
weight loss and shedding. 
Rodent chow. Standard rodent chow was purchased from Research Diets Inc. 
(New Brunswick, NJ). The manufacturer infused the PTU diet with 0.5g PTU per 
kilogram of chow, and the PTU/thyroxine diet with 0.5g PTU plus 0.5g thyroxine per kg 
of chow. Thus, three separate types of chow were received: PTU-infused, PTU/thyroxine 
infused, and control chow.  
 Food was weighed and refilled for each cage at the start of every week. The 
amount of food (g) eaten each week was recorded in order to estimate drug dosages, as 
well as track any differences in food consumption between groups. 
Behavioral measures. 




Saccharin preference test. The procedure used for the saccharin preference test 
was based on methods described by Sadler and Bailey (2016). Both sucrose and saccharin 
have been utilized as sweeteners in this test, but the present study used saccharin to avoid 
the potential confound of caloric value. Approximately 4 weeks after the start of 
treatment, mice were transferred to cages containing one bottle of tap water and one 
bottle filled with a 0.03% saccharin solution. This concentration of saccharin was 
determined based on the results of previous pilot testing (see Appendix A). Mice were 
habituated to this solution with their cage mates for approximately 12 hours, after which 
they returned to their regular cages with their normal drinking water.  
Saccharin preference testing began 3 days after the habituation period. Mice were 
housed in individual cages for approximately 12 hours (overnight) with a bottle of tap 
water and a bottle of saccharin solution. Cage dimensions were approximately 30.8 cm x 
30.8 cm x 14.3 cm. Bottles of saccharin were randomly placed on either the left or right 
side of the cage. The bottles were weighed before and after the testing period to 
determine the volume of liquid consumed. Because there were not enough cages 
available to individually house each mouse, half were randomly assigned to test the 
following night. A “preference score” was calculated for each mouse by dividing the 
amount of saccharin solution consumed by the total amount of consumed solution. Lower 
preference scores for saccharin therefore reflected higher levels of anhedonia. As a 
secondary variable, we also recorded to total amount of solution consumed.  
It should also be noted that as the saccharin preference tests were being 
conducted, we noticed that the tap and saccharin solutions tended to drip out of the 
bottles unintentionally. This seemed to be partially due to the cage design (Thoren 




Caging Systems, Inc. Hazelton, PA), as bottles needed to be inverted to fit into position. 
Liquid also tended to spill when the cages were being arranged on the storage shelves, 
which seemed to reflect a flaw in the bottles and/or lids themselves. This spillage was 
especially problematic given that our measures directly depended on the bottle weights. 
The values we report do not account for such spillage, however, as spillage amounts were 
found to be normally distributed and therefore equally present in each treatment group. 
Appendix B reviews the empirical investigation conducted to address this concern. 
EPM. The EPM was conducted approximately 5 weeks after the start of 
experimental treatment, and began after saccharin preference testing was complete. The 
maze (Maze Engineers, Boston, MA) consisted of 4 arms, each 35 inches long and 5 cm 
wide. The two closed arms contained walls on either side that were 40 cm in height. The 
arms and walls were constructed with blue Plexiglass, which allowed the mice to stand 
out on the SMART video system used to track mouse movement (described under 
“software”). The four arms extended out from a small central area of 5 square cm, and the 
entire maze was elevated at a height of 61cm above the ground by four metal legs (see 
Appendix B for a scaled drawing of the apparatus).  
Each mouse was placed by the experimenter at the central area of the maze facing 
one of the open arms and allowed to explore freely for 3 minutes. Behavior was 
monitored by both a trained observer and a digital video tracking system. The maze was 
wiped down with a prepared disinfectant solution between each mouse trial, containing 
21.4% potassium peroxymonosulfate and 1.5% sodium chloride. The primary variable of 
interest was the amount of time spent in the open versus the closed arms. Each mouse 
was given a “percent open” score by dividing the amount of time spent in the open arms 




by the total time spent in the maze. Higher scores reflect lower levels of anxiety, and 
mice in the hypothyroid condition were expected to yield significantly lower scores. 
Total distance traveled was measured as a secondary variable to see whether PTU 
affected general locomotion. 
 OP.  The OP was conducted in a 40x40x30 cm open field apparatus (Maze 
Engineers, Boston, MA) constructed from blue Plexiglass (see Appendix B for a scaled 
drawing). Black and white laminated shapes were taped to the walls to provide spatial 
cues. Small, colorful ceramic flamingo figurines were used as stimuli, which were found 
to encourage exploration in pilot tests (Appendix A). Between each training and testing 
session, both the arena and the figurines were thoroughly cleaned with prepared 
disinfectant.  
 Mice first explored the arena during a 5-minute information trial. A researcher 
placed each mouse at the center of the open field. Two ceramic flamingos were set up 
several inches apart in their initial locations. The mice were then put back in their cages 
for a 1-hour inter-trial interval, after which they re-entered the field for a 5-minute 
retention trial. Before the retention trial began, one of the flamingos was moved to its 
pre-established “novel” location closer to the opposite wall. Care was taken to ensure that 
during this novel condition, each flamingo was approximately the same distance away 
from a corner. Figure 2 describes how the objects were positioned during information and 
retention trials. For a scaled drawing of the open field apparatus, see Appendix B.  
 All trials were digitally recorded via the SMART video tracking system (see 
“Software”). A trained data coder went through each video file and used a stopwatch 
application to manually record how much time was spent exploring each object. Behavior 




was considered to be exploratory if the mouse’s head was clearly oriented toward the 
object. Behavior was not counted if the head orientation was unclear from the video, or if 
the mouse was sitting directly on top of an object.  Each video file was labeled with a 
randomly assigned number to ensure that the data coder was blind to experimental 
condition.  
 The primary dependent variable was the amount of time spent exploring the 
object in the new location relative to the object in the familiar location. This was 
calculated by dividing the total time spent with the object in the new location by the total 
amount of exploration time. Lower scores therefore reflected more spatial memory 
impairment. As a secondary variable, we also measured the total amount of time spent 
investigating the objects. 
Software. Digital video tracking software was used during the EPM and OP tests 
to record behavioral data. The SMART video tracking system by Harvard Apparatus used 
a digital camera to track mouse movement in real time. The system was calibrated to a 
stationary image of the Plexiglass such that when the mice were added, movement of 
their darker pixels could be easily followed. Behaviors were additionally monitored by 
trained observers to ensure accuracy. 
Procedure and Design 
This study used a between-subjects experimental design. When mice reached 8 
weeks of age, they were randomly assigned to either a PTU, PTU/thyroxine (henceforth 
PTU/thy), or control group (n = 15 per group). PTU mice were referred to as the 
“hypothyroid” group, while PTU/thy mice were meant to be “euthyroid.” However, 
because PTU/thy mice showed unanticipated signs of hyperthyroidism, it is clearer to 




refer to each group by their experimental treatment rather than their thyroid status. See 
Table 2 for an additional overview of the study design.  
Mice of the same group were housed together in order to simplify the feeding 
process. There were thus three cages of each experimental group with five mice in each 
cage. On the first day of treatment, mice underwent a noninvasive ear notching procedure 
so that each mouse could be individually identified.  The experimental treatment period 
lasted for 4 weeks. Mice were weighed and observed 2-3 times a week, and food was 
weighed and refilled at the start of each week. Mice had free access to water and were 
maintained in accordance to IACUC standards. 
 Behavioral tests took place 4 weeks after the start of treatment at 12 weeks of age. 
Mice remained on their regular experimental diets during this testing period. Saccharin 
habituation was completed first, followed by the saccharin preference test and EPM. Due 
to concerns of observed weight loss, all PTU/thy mice were sacrificed before OP testing 
occurred. Thus, there is no spatial memory data available for PTU/thy mice. The 
observed weight loss in PTU/thy mice will be addressed further in the results and 
discussion sections.  The remaining PTU and control mice were sacrificed after the OPT 
was complete. Figure 3 provides a timeline of experimental procedures.  
 Tissue collection. After behavioral tests were completed, mice were anesthetized 
with CO2 and sacrificed by decapitation. Brains were quickly separated from the skull 
and placed on a thin sheet of plastic situated on a bed of crushed dry ice. When the brains 
were completely frozen after about 15 minutes, they were transferred to small glass tubes 
and stored at -20°C. Tissue from the prefrontal cortex and hippocampus were sliced 10 
micrometers thick with a cryostat and mounted onto glass slides for future binding 




experiments. Appendix D describes the procedures used for tissue preparation, and 
Appendix E gives a proposed methodology for examining AMPA receptor binding using 
autoradiography. Although binding was not assessed in the present study, we believe it to 
be a valuable extension of this research.   
Statistical Analyses  
Attrition.  Two mice in the PTU/thy group were excluded from the behavioral 
analyses. One was found deceased shortly before the start of behavioral testing, and one 
was sacrificed the same day after a 20% decrease from maximum body weight was 
observed. This degree of weight loss requires animals to be humanely euthanized 
according to ethical guidelines. These two mice were also excluded from analyses 
involving body weight, as they were missing data from the 12-week-old time point.  
Behavioral data. Analyses were conducted to compare variables of interest 
among the three conditions (PTU, PTU/thy, and control). For the behavioral tests, the 
primary variables of interest were the following: preference score (saccharin preference 
test), time spent in the open arms of the maze (EPM), and spatial memory impairment 
(OPT). Formulas used to calculate each score are provided below. Secondary analyses 
were conducted for additional variables of interest: total amount of solution consumed in 
the saccharin preference test, total distance traveled in the EPM, and total exploration 
time during the OP. P-values were not adjusted for these secondary analyses. All 
behavioral data was analyzed with R Studio using the following procedure. 
 First, a Lilliefors test determined whether the data was normally distributed. The 
test was run on the residual values (as opposed to the raw values) by first subtracting each 




value by the group mean. This step was taken remove the possibility that group 
differences stemming from treatment effects could affect the normality analysis. 
If the data proved normal, they were screened for outliers using Pierce’s criterion.  
Outliers were excluded from analysis but reported in the supplemental materials (see 
Appendix E). A one-way, between-subjects ANOVA was then calculated for each 
variable and followed by Tukey-Kramer post-hoc tests if necessary. Independent samples 
t-tests were used for OP-related dependent measures, because there was only data from 
two experimental groups available in this task. This change was required because 
unforeseen events required euthanasia of mice in one treatment group prior to starting 
this test (see discussion below in the OP/Spatial Memory section) 
 Non-normal data was analyzed with the Kruskal-Wallis H test, followed by a 
Mann-Whitney U post-hoc. This nonparametric test was used because it does not assume 
normality. Additionally, no outliers were eliminated from non-normal data because 
Pierce’s criterion detects outliers at an unacceptably high rate in non-normal data. Effect 
sizes are reported in terms of eta2 for normal behavioral data, but these values could not 
be calculated for non-normally distributed data.  
Behavioral score formulas. For primary variables: Saccharin preference (%) was 
defined as the total saccharin water intake (in grams) divided by the total amount of 
solution consumed (saccharin intake + tap intake) * 100. Percentage of time spent in the 
open arms of the EPM was similarly defined as the time (in seconds) spent in the open 
arms divided by the sum of time spent in the open and closed arms. Novel object 
preference, or spatial memory, was expressed by the amount of time spent exploring the 
novel object (in seconds) divided by the total amount of exploration time. For secondary 




variables: Total consumption in the saccharin preference test was obtained by adding the 
amount of tap water consumed with the amount of saccharin water consumed. Total 
distance traveled in the EPM was the sum of distances traveled in the closed arms and the 
open arms. Total exploration time on the OP was the sum of time the mice spent 
exploring objects in the both the familiar and novel locations.  
 Food consumption and body weight. Body weight and food consumption data 
were analyzed to examine potential treatment-related effects. For each week beginning 
with the first week of treatment, average body weight was calculated for each mouse 
from the 2-3 times they had been weighed. Food consumption was estimated by 
determining the difference in cage food weight between the start and end of each week, 
and then dividing the obtained value by the number of mice in the cage. A mixed 
between-within subjects ANOVA was performed in SPSS to examine the effects of time 
and group on each measure. Pairwise comparisons were adjusted with a Bonferroni 




Saccharin preference/anhedonia. A Lilliefors test revealed a non-normal 
distribution among saccharin preference scores (D = 0.15, p = 0.02). A nonparametric 
Kruskal-Wallis test found significant differences between groups (2 (2, n = 42) = 15.86, 
p < 0.001). Further analysis with a Mann-Whitney U post-hoc found that PTU/thyroxine 
mice had significantly higher preference scores than both the hypothyroid and control 
groups (U = 151, p = 0.002; U = 161, p < 0.001, respectively). Contrary to our 




hypothesis, however, PTU mice did not differ in preference with controls. These data are 
summarized in Figure 4. 
As a secondary variable, we also looked at the total amount of water consumed 
(both saccharin and tap). A one-way ANOVA showed a significant effect of treatment 
group total consumption (F(2,38) = 9.1, p < 0.001, eta2 = 0.32), and a Tukey HSD post-
hoc revealed that PTU/thyroxine mice drank significantly more than the other two groups 
(M = 18.49, SD = 3.47). Although PTU mice consumed less than controls, this difference 
was not significant (M = 14.69, SD = 0.98; M = 16.31, SD = 1.91, respectively). 
Elevated Plus-Maze/anxiety. Statistical results from the EPM are represented in 
Figure 5. The percentage of time spent in the open arms of the maze – with lower 
percentages reflecting higher anxiety – was significantly different between treatment 
groups (F(2,37) = 7.403, p = 0.002, eta2 = 0.286). As predicted, hypothyroid mice spent 
significantly less time in the open arms compared to the other groups (M = 17.67%, SD = 
0.12 for control mice; M = 5.38%, SD = 0.06 for PTU mice; M = 22.54%, SD = 0.14 for 
PTU/thyroxine mice). Secondary analyses revealed that the total distance traveled (cm) 
also differed between groups (F(2,39) = 6.30, p = 0.004), with significantly lower travel 
distance for PTU mice (M = 518.47, SD = 54) than PTU/thyroxine mice (M = 622.79, SD 
= 96.4). However, neither group differed significantly from controls (M = 581.18, SD = 
80).  
Object placement/spatial memory. There was no difference in either novel 
object exploration time (t(24.1) = -0.39, p = 0.7) or total exploration time (t(24.1) = 
0.067, p = 0.95) between the PTU and control groups. Degrees of freedom were adjusted 
in order to control for heterogeneity of variance. These data are shown in Figure 6. 





General observations. During the first week of experimental treatment, 
researchers noted that PTU/thy mice appeared to be more aggressive than mice in the 
other groups; specifically, they were noticeably more physical with their cage-mates and 
more difficult for the experimenters to handle. This observation persisted over the next 
few weeks. During the third week of treatment, it was also observed that PTU/thy mice 
had a noticeable decrease in fur quality. Researchers reported clumps of fur throughout 
the cages and described a “shaggy” and “ragged” appearance. It was also during this time 
that researchers noticed that PTU/thy mice were smaller than the others. 
 At the end of the fourth week of treatment (right before the onset of behavioral 
testing), one of the PTU/thy mice was found deceased. Another was found to be 20% 
below their maximum body weight and was therefore euthanized according to ethical 
guidelines. Several other PTU/thyroxine mice had dropped 10% below their maximum 
weight, and it seemed evident that weights would continue to decrease. The remaining 
PTU/thy mice were able to perform the saccharin preference and EPM tests, but 
researchers and supervisors decided to euthanize the group before putting them through 
the lengthier OPT. It should therefore be noted that PTU/thy mice were euthanized 
approximately a week before the rest of the mice. 
Body weight. Figure 7 shows average body weight (g) during experimental 
treatment. A mixed between-within subjects ANOVA found significant main effects for 
age (F(2.85, 114.1) = 55.08, p < 0.001, partial eta
2 = 0.58) and group (F(2,40) = 5.2, p = 
0.01, partial eta2 = 0.21), as well as a significant interaction between the two (F(5.7, 
114.1) = 83.99, p < 0.001, partial eta
2 = 0.81.).  Bonferroni-adjusted pairwise 




comparisons found that on average, PTU/thy mice weighed significantly less than PTU 
mice (M = 22.25g, SD = 1.54 compared to M = 23.62g, SD = 1.37) and controls (M = 
23.84g, SD = 2.08, p = 0.014).  
Food consumption. Figure 8 shows the average food consumption (g) per mouse, 
estimated from per cage consumption, in each treatment group over the course of 
experimental treatment. A two factor mixed between-within subjects ANOVA revealed 
that treatment group (F(2,6) = 105.90, p < 0.001, partial eta2 = 0.97) and an age/group 
interaction (F(2.4, 7.2) = 10.60, p = 0.006, partial eta2 = 0.78) both had significant effects 
on the amount of food consumed (degrees of freedom were adjusted for heterogeneity of 
variance). Mouse age did not have a main effect on consumption alone. Bonferroni-
adjusted pairwise comparisons showed that on average, PTU/thy mice consumed 
significantly more than PTU mice (M = 28.12g, SD = 2.89 compared to M = 18.07g, SD 
= 1.27, p < 0.001) and controls (M = 19.89g, SD = 1.16, p < 0.001). Food consumption 
differences between the PTU and PTU/thy groups are especially important to note, as this 
indicates a difference in estimated drug dosages as well. Table 1 describes the estimated 
dosages of treatments for each group.  
Discussion  
We hypothesized that inducing a hypothyroid state in mice through administration 
of PTU would induce reductions in saccharin preference, increased anxiety-like behavior 
in the EPM, and impaired performance of the object placement task in comparison to 
controls. Furthermore, we hypothesized that restoring thyroid function through thyroxine 
treatment would attenuate these differences. Our results found that treatment with PTU 
failed to induce differences in saccharin preference or object placement performance 




compared to control mice. However, PTU-treated animals did exhibit a decrease in the 
percentage of time spent in the open arms of the EPM relative to controls, which can be 
interpreted as an increase in anxiety-like behavior. In addition, mice given the 
PTU/thyroxine treatment had a significantly higher preference for saccharin, as well as 
significantly higher levels of water consumption, compared to control and hypothyroid 
mice. Furthermore, the PTU/thyroxine group performed at equal levels to controls in the 
EPM, suggesting that increased thyroid function did, indeed, attenuate the anxiogenic 
effects of PTU treatment.  
Interpretation of our results is complicated by findings from the PTU/thyroxine 
group. TH-treated groups of hypothyroid animals are typically included in these types of 
designs to test whether restoring TH function can block potential hypothyroidism-related 
effects. In this regard, this study’s addition of T4 to experimental treatment seemed to 
normalize the anxiety-like behaviors associated with PTU in the EPM task. However, 
observations of increased food take, significant body weight reduction, and poor fur 
quality indicated that mice within the PTU/thyroxine group exhibited some hyperthyroid-
like symptoms. Although exact serum measurements of TH levels are unavailable at this 
time, we inferred from these observations that the PTU/thyroxine dose used here likely 
raised TH concentrations above normal levels. A hyperthyroid state therefore restored 
responses to baseline levels during the EPM, but raised responses above baseline levels in 
the saccharin preference test.  
Taken together, these data suggest that our hypotheses were only partially 
supported and hint at a complicated relationship between thyroid status and our three 
measures of depression-like symptoms. The findings suggest that TH deficiency could 




result in anxiety-like behaviors, but has little effect on measures of spatial memory and 
anhedonia. TH overstimulation, on the other hand, could lead to increased preference for 
sweet solutions – as well as prevent hypothyroidism-induced anxiety without necessarily 
affecting anxiety in itself. Such results raise broader questions about how individual 
facets of MDD could have different types of relationships with TH function. These 
questions are considered below in greater detail as they relate to each behavioral measure. 
Saccharin Preference/Anhedonia 
 Primary measure: Saccharin preference. In the saccharin preference test, 
decreased preference for sweetened versus tap water is thought to reflect a depression-
like reduction of enjoyment to pleasurable stimuli (Willner et al., 1987). This study did 
not find the expected relationship between hypothyroidism and anhedonia, but it did find 
an increased preference for saccharin in mice treated with a PTU/thyroxine combination. 
The negative findings in the PTU group are inconsistent with several studies that reported 
decreased sucrose or saccharin preference in hypothyroid mice (e.g. Rivlin et al., 1997; 
Yu et al., 2014; Ge et al., 2016). However, the majority of studies demonstrating 
depressive-like behavior in hypothyroid models have done so using fundamentally 
different behavioral paradigms – such as the forced swim test (FST) and tail suspension 
test (TST) – which measure depression in terms of immobility time (e.g. Wilcoxon et al., 
2007; Pilhatsch et al., 2010; Ge et al., 2013; Ge et al., 2016; Bocco et al., 2016). A 
particular study by Ge et al. (2013) found that hypothyroid mice exhibited significant 
depressive-like behavior in the FST and TST but showed no behavioral changes in tests 
of sucrose preference. They additionally reported decreased hippocampal T3 
concentrations in hypothyroid rats, which correlated with immobility time in the FST and 




TST but not with levels of anhedonia. Taken together, suggest that reduced TH levels 
could be more strongly associated with measures of behavioral despair than with 
anhedonia-specific measures of depression.  
 Alternatively, preference for sweetened water could be an inappropriate way to 
operationalize anhedonia in hypothyroid models. There is some evidence that THs 
influence taste perception in both humans (McConnell, Menendez, Smith, Henkin, & 
Rivlin, 1975) and animals (Rivlin et al., 1977), which raises the possibility that 
differences in saccharin preference could be attributed to fondness for different tastes 
rather than a reflection of anhedonia. In one experiment, Rivlin et al. (1977) found that 
hypothyroid rats had a significantly lower preference for sweetened water but a higher 
preference for water made bitter with quinine sulfate. Treatment with TH normalized the 
preferences for both bitter and sweetened water back to control levels, suggesting that TH 
concentrations could affect inclinations toward particular flavors. If increased TH levels 
are in fact associated with a fondness for sweet flavors, this could reasonably explain 
why PTU/thyroxine mice had a higher saccharin preference than the other groups in the 
present study. It would also make sense, in this case, for thyroxine to elicit higher 
saccharin preference despite the absence of PTU-induced anhedonia. Furthermore, it 
would help explain why the PTU/thyroxine combination raised saccharin preference 
above control levels but did not show a similarly increased effect on the EPM. 
 There are several other ways in which these saccharin preference findings can be 
interpreted. One possibility is that the present dose of PTU was too low to detect 
hypothyroidism-induced anhedonia, and a higher dose would have revealed the expected 
effects. It is also possible that processes underlying the anxiety- and anhedonia-related 




behaviors assessed in the current study have qualitatively different relationships with TH 
function. EPM-related processes, for example, could have been more sensitive to the TH 
deficiency than the specific mechanisms utilized in the saccharin preference test. In 
support of this idea, Pilhatsch et al. (2010) found that treating euthyroid mice with T3 had 
significant effects on behavioral measures of depression but not on behavioral measures 
of anxiety – despite the fact that their hypothyroid model had significant effects on both. 
This emphasizes the idea that THs may not necessarily have identical effects on different 
behavioral processes. 
 Secondary measure: Total consumption.  PTU/thyroxine mice additionally 
consumed significantly more water – both tap and sweetened – than hypothyroid and 
control mice. This finding is not surprising given that PTU/thyroxine mice also consumed 
significantly more food than the other groups throughout the study. They additionally 
weighed significantly less than the other groups of mice and exhibited rapid weight loss 
during the last week of treatment; which, when taken together, is indicative of high 
metabolic activity. This is also consistent with unsystematic observations of increased 
brown adipose tissue of PTU/thyroxine mice, which is known to drive metabolic activity. 
While increased food intake and metabolic rates can reasonably explain an increase in 
water consumption during the saccharin preference test, they importantly do not explain 
why PTU/thyroxine mice preferred sweetened water to tap water to such a high degree. 
Saccharin was intentionally used instead of sucrose in the present study because it lacks 
caloric value, so increased preference for saccharin cannot be attributed to caloric intake. 
 Methodological concerns. In the present study, there were several concerns 
worth discussing that arose during saccharin preference testing. Appendix C elaborates 




on the issue of water spillage during the procedure, noting how solution tended to drip 
out of the test bottles as they were being inverted into each cage. The saccharin 
preference procedure was replicated with empty cages in order to estimate the average 
amounts of solution lost overnight by reasons other than mouse consumption. Because 
spillage amounts were distributed normally across the cages – and there is no reason to 
suspect that experimental groups were differentially affected by this issue – it was found 
unlikely that water loss affected the general patterns of saccharin preference that were 
observed between the treatment groups. However, it is possible that the water loss 
decreased the obtained values of saccharin preference scores. Pilot test data found 
saccharin preference to be around 77% (Appendix A), while control mice in the present 
study had an average preference of only 58%. The PTU/thyroxine group, which showed 
the highest levels of preference, additionally had 10% less preference than the pilot mice. 
Since mice were tested five to a cage during these preliminary tests, the problem of 
spillage was not as apparent.  
 In addition, the test procedure was slightly modified from the methods established 
a priori due to health concerns in the PTU/thyroxine group. This group exhibited 
dramatic weight loss during the final week of treatment, and one mouse was found 
deceased shortly before behavioral tests began. Another was humanely euthanized before 
the testing procedures after losing over 20% of its maximum body weight, which is 
ethically required according to IACUC protocol. The original procedure for saccharin 
preference involved depriving mice of water overnight, and then exposing them to bottles 
of sweetened and tap water for a period of 2-4 hours. Because drops in body weight are 
common in mice after overnight water deprivation, it was decided this would pose too big 




a risk for the PTU/thyroxine mice. Instead, mice were housed in individual cages 
overnight with the two water types and each bottle was subsequently weighed the 
following morning. Both these procedures have been utilized in the literature, so it is 
unlikely that this change altered the results. 
EPM/Anxiety 
Primary measure: Open arm time. The primary finding in this experiment is 
that PTU-induced hypothyroidism had a significant effect on anxiety-like behavior in the 
EPM. Hypothyroid mice spent a significantly lower percentage of time in the maze’s 
open arms compared to the other groups; which, in this paradigm, is thought to reflect 
more fear and avoidance for unfamiliar places (Walf & Frye, 2007). Anxiolytic 
treatments like diazepam (Pellow, Chopin, File, & Briley, 1985) and chronic fluoxetine 
(Silva et al., 1999) have consistently been found to reverse this effect, supporting the 
predictive validity of this measure.  
Other labs have reported similar findings associating animal models of 
hypothyroidism with a range of different measures of anxiety (e.g. Pilhatsch et al., 2010; 
Buras et al., 2013; Bocco et al., 2016; Ge, Xu, Qin, Cheng, & Chen, 2016). On one hand, 
the fact that different behavioral paradigms have been used to support a relationship 
between anxiety and hypothyroidism seems to suggest that their association is quite 
robust. For example, Buras et al. (2013) found consistent patterns of hypothyroidism-
induced anxiety on four behavioral tasks: the EPM, open field test, light-dark transition, 
and fear conditioning. Montero-Pedrazuela et al. (2011) found these associations were 
also present in a more complex conditioning paradigm wherein hypothyroid mice had 
increased auditory and contextual fear memory (operationalized by freezing behavior) 3 




weeks after conditioning began. Pilhatch et al. (2010) used both a dark-light box and a 
startle response test, which examine very different behavioral responses, to in order 
demonstrate hypothyroidism-induced anxiety. Together, these findings indicate an effect 
of TH deficiency on anxiety that goes beyond the EPM-specific definition of staying in 
the closed, safe arms of a plus-shaped maze.  
Closer inspection of each study’s findings, however, raises questions about just 
how generalizable the thyroid/anxiety relationship is. There are a number of different 
variables that can “indicate” anxiety within the EPM alone, so operationalization of the 
construct can therefore vary considerably across studies. One report found hypothyroid 
mice had increased anxiety through greater amounts of freezing and less “head dipping” 
into the maze’s open arms, but the percentage of time spent in the open areas was not 
significantly reduced as it was in the current study (Bocco et al., 2016). Another only 
found differences between hypothyroid and control mice in the amount of entries into 
closed arms (Mundstock Dias et al., 2012). There is a limited amount of research 
specifically addressing anxiety in hypothyroid animal models; so despite some of the 
promising findings that were discussed, it is important to keep in mind that differences in 
behavioral paradigms, definitions of effects, and actual hypothyroid models could 
exaggerate any perceived effects on anxiety that thyroid status may have. Furthermore, a 
study by Yu et al. (2015) notably found significantly increased EPM anxiety in 
hyperthyroid mice while hypothyroidism had an anxiolytic effect.  
The effects of hyperthyroidism on anxiety also raise questions about how THs 
mediate the construct. In the present study, PTU/thyroxine mice displayed several signs 
of hyperthyroidism that suggested an overproduction or overactive functioning of THs. 




Purposely induced hyperthyroidism in the literature has led to increased anxiety in some 
studies (e.g. Yu et al., 2015) and decreased anxiety in others (e.g. Stohn et al., 2016), 
with key differences in the specific hyperthyroidism models used. In this study, 
PTU/thyroxine mice did not differ with controls in terms of anxiety-like behaviors; 
however, they did have significantly decreased anxiety compared with mice in the 
hypothyroid group. Since the present study was not designed to induce hyperthyroidism, 
it is likely that the thyroxine dose used here was not high enough to produce a significant 
hyperthyroid-induced effect. Our results are similar to those of Buras et al. (2016) who 
reported that although not all differences were necessarily significant, there was a 
consistent pattern of euthyroid mice displaying anxiety at levels between hypothyroid and 
TH-treated animals. They suggested that TH levels likely have a gradient-like of effect on 
anxiety, which the patterns found here seem to support as well.  
Because the present study did not find similar effects of hypothyroidism on 
anhedonia or spatial memory, our results seem to suggest that TH deficiency has specific 
effects on anxiety-related processes. It is possible that the widely reported relationships 
between hypothyroidism and MDD can primarily be attributed to the anxiety-related 
symptoms that accompany depression. This idea is supported by findings from Bathla et 
al. (2016) that 73% of hypothyroid patients reported having some degree of anxiety on 
the HAM-A compared to 60% reporting some degree of depression on the HDRS. There 
was additionally an extremely high correlation (r = 0.93) between scores on the two 
measures, which helped to illustrate the strong overlap in responses to items targeting 
symptoms of anxiety. Furthermore, Montero-Pedrazuela et al.’s (2011) work on fear 
memory demonstrated higher corticosterone plasma levels in hypothyroid rats after fear 




conditioning as well as increased glucocorticoid receptor expression in the amygdala. 
Because elevated cortisol and glucocorticoid levels have neurotoxic effects that lead to 
decreased synapse formation and cell survival (Liu, 2017), it is tempting to speculate that 
the depressive-like reductions in synaptogenesis and cell signaling found in hypothyroid 
models could be secondary to more direct effects of hypothyroidism on anxious 
behaviors. This speculation speaks far past any concrete evidence in the literature or the 
present study, however, and further research would be warranted to examine the 
possibility.  
It is more likely that hypothyroidism’s selective effect on anxiety in the current 
study reflects the PTU dosage used, problems with methodology, or limitations of the 
specific depression measure. There is one study that reported higher TSH and T4 levels 
in patients specifically with panic disorder which correlated significantly with anxiety 
severity (Kikuchi et al., 2005); but the majority of reported relationships between TH 
function and anxiety – both in human populations and animal models – are accompanied 
by strong relationships to depression as well.  
Secondary measure: Locomotor behavior. In addition, PTU-treated mice 
exhibited significantly lower total distance traveled compared to PTU/thyroxine mice but 
not controls. Because traveling less in general and slower travel rates could be 
confounding explanations for less time spent in the open arms, these data help to support 
the contention that underlying differences in specific anxiety processes drove the 
observed behavioral differences. Moreover, the observed differences in travel distance 
could be related to fatigue, which is commonly associated with hypothyroidism (Nussey 
& Whitehead, 2001). However, these data could also represent lower body temperatures, 




which are also a symptom of hypothyroidism and are commonly associated with reduced 
locomotor activity in rodents (Venero et al., 2005). 
OP/Spatial Memory 
Primary measure: Novel object exploration. There were no differences in novel 
object exploration time between hypothyroid and control mice in the OPT. This study’s 
failure to demonstrate a significant relationship between spatial memory and TH function 
is surprising, especially given the vast amount of literature connecting thyroid function to 
hippocampal processes. The hippocampus has a notably high amount of TH receptors, 
making it a particularly important target region for TH activity (Raymaekers & Darras, 
2017). Several studies have accordingly demonstrated spatial memory impairment in 
hypothyroid animals that correlate with impaired hippocampal LTP – both of which are 
restored by TH treatment (Alzoubi et al., 2009; Dong et al., 2011). It is possible that the 
discrepancy between previous studies and the current findings has to do with the 
particular spatial memory task utilized. For instance, the majority of research 
demonstrating impaired spatial memory in hypothyroid models used radial water maze 
tasks (e.g. Wilcoxon, Nadolski, Samarut, Chassande, & Redei, 2007; Alzoubi et al., 
2009; Galton, Schneider, Clark, & Germain, 2009) rather than novel object placement. 
However, the present OP data were particularly concerning in that even control 
mice did not show the expected preference for novel object placement. This finding 
contradicts the natural preference for novel over familiar locations reported in the OPT 
literature (e.g. Mumby, Gaskin, Glenn, Schramek, & Lehmann, 2002), as well as findings 
from our own extensive pilot tests (Appendix A). It is highly likely that the present 
results were influenced by temperature and humidity problems that arose in the vivarium 




on the days that the OPT was being conducted. Experimental animals must be housed 
under heavily regulated conditions, and the increased room temperatures observed during 
OP testing led to several interruptions in the procedure by maintenance and veterinary 
staff. It also likely led to behavioral and biological alterations that make the validity of 
the present findings questionable.  
There are other methodological aspects of the OPT that could have contributed to 
our negative findings.  For example, the video tracking software used in the EPM was not 
useful for measuring object exploration in this particular task. Exploration was therefore 
coded entirely by hand using recorded tapes of experimental sessions; and because all 
tests were conducted in dim lighting conditions, video quality was not always clear. 
Erring on the side of caution, behavior was not coded as exploration if head orientation 
was not completely evident. It is therefore possible that not all object exploration was 
properly accounted for in the present data. Additionally, mice were not habituated to the 
open field area before the information session due to time constraints. A habituation 
session would have further familiarized the mice with the testing environment, and 
potentially resulted in more exploratory behavior for the objects once they were 
introduced. However, a true effect of hypothyroidism should have revealed behavioral 
differences between groups whether or not a habituation session was included.  
There is additionally no spatial memory data for PTU/thyroxine mice, as rapid 
weight loss required them to be euthanized before the test could be conducted. This is 
particularly unfortunate, as object exploration data from this group could have provided 
further insight into the meaning of our negative results. If PTU/thyroxine mice exhibited 
a higher novel object preference than the other groups as they did in the saccharin 




preference test, for example, it would strongly suggest that the PTU/thyroxine treatment 
consistently results in altered behavioral responses. It would also raise the possibility that 
the PTU dose was too low to detect saccharin preference and spatial memory changes, 
but that these two tests are nevertheless mediated by TH activity. Furthermore, equal 
performance to control and hypothyroid groups would provide further evidence that our 
results were confounded by the temperature increase.  
 Secondary measure: Total exploration time. Hypothyroid mice additionally did 
not differ from controls in terms of total exploration time. Unfortunately, this finding 
does not hold much value given the testing conditions described. Exploration time could 
have also been raised or altered with the addition of a habituation period, which should be 
included in future experiments.  
Limitations and Future Directions  
 Drug treatments. The biggest limitation of this study was that the thyroxine 
concentration used in our model was dramatically miscalculated. A daily dose of 50-70 
µg/kg of body weight was estimated from previous literature, but the actual dose 
consumed in this study was calculated to be 87.57 mg/kg of body weight. This dose of 
thyroxine, which is markedly higher than expected, resulted in hyperthyroid-like 
symptoms in the PTU/thyroxine group. There were several signs of treatment-related side 
effects during the beginning of the treatment period; for example, they tended to consume 
more food than the other groups, their fur became noticeably ragged, and they were 
somewhat more difficult to handle. During the fourth week of treatment, body weight 
began rapidly decreasing and one of the mice was lost through attrition. IACUC ethical 
guidelines require that mice with a 20% decrease in body weight be humanely sacrificed 




to minimize potential suffering, and the research team and veterinarian accordingly 
euthanized all PTU/thyroxine mice before behavioral tests were finished.  
The hyperthyroid symptoms in PTU/thyroxine mice makes their observed 
behavioral effects particularly difficult to interpret. PTU/thyroxine treatment appeared to 
normalize the anxiety-like behaviors seen in PTU mice, for example, but one would 
expect a hyperthyroid model to reverse anxiety-like behavior to a level below that of 
controls. In the saccharin preference test, PTU/thyroxine treatment contrarily raised 
saccharin preference significantly above control levels. One major challenge to 
interpreting these results is that it is unclear how TH concentrations in PTU/thyroxine 
mice compare to that normal, euthyroid levels.  
Questions about the strength of hypo- and hyperthyroid effects could be addressed 
in future studies by including full dose-response curves to both PTU and thyroxine. 
Comparing the behaviors of a PTU/low-thyroxine to a PTU/high-thyroxine group could 
provide more information about how TH treatment affects hypothyroid models. 
Additionally, including a low-PTU and high-PTU group could examine whether the 
strength of behavioral effects depend on the strength of PTU administration. This 
information is especially valuable to have in the absence of serum TH and TSH 
measurements, which is another important limitation in this study. It should be noted, 
however, that blood samples were collected to examine TH concentrations for future 
extension of this research. Serum levels of T3 and T4 can then be examined to see 
whether there was a relationship between TH concentration and specific behavioral 
responses.  




Finally, the PTU and thyroxine treatments used here do little to differentiate TH 
in the brain vs. TH in the periphery. The present study was designed to investigate a 
general hypothyroid model, but future studies could benefit from specifically examining 
TH function in the CNS. Mechanisms targeted by the thyroid that influence depressive-
like behavior are more likely related to brain activity than that in the peripheral tissue, 
and thyroid dysfunction in human MDD patients is rarely an overt thyroid disorder (e.g. 
Hage & Azar, 2012). One particular study achieved this using mice with selective D2 
inactivation in astrocytes (Bocco et al., 2016) and another used mice with the mutant TR 
α1 (Pilhatsch et al., 2010), which are two interesting models to consider. 
Behavioral tests. Unfortunately, very little information about spatial memory was 
uncovered in the present study due to several limitations in the OPT. First of all, there is 
no behavioral data from PTU/thyroxine in this paradigm which limits our understanding 
of how TH function affected exploratory behavior. Second, increased temperatures in the 
vivarium during testing could have likely influenced the observed behavior. Although 
veterinary staff advised us to postpone behavioral testing, over half of the mice had been 
tested in the high-temperature environment by that point. It was our contention that 
changing testing conditions halfway through the procedure would ultimately be more 
detrimental to the experiment. It is also possible that there simply was not an effect of 
PTU on OPT performance, but the fact that even control mice did not prefer the novel 
placement strongly suggests that the environmental variables negatively affected 
behavior. 
 Additionally, a close review of the literature raised the question of whether 
anhedonia, as measured by the saccharin preference test, was the best choice in our 




behavioral operationalization of depression symptoms. While decreased 
sucrose/saccharin preference has been found in some hypothyroid models (Yu et al., 
2014; Ge et al., 2016), the forced swim and tail suspension paradigms have been found to 
be more strongly affected by hypothyroid treatment (Ge et al., 2014). Additionally, the 
strong relationship between thyroid function and metabolism could be confounding in a 
saccharin preference measure. It is highly likely that the increased saccharin preference 
and water consumption in PTU/thyroxine mice had more to do with metabolic activity 
than decreased anhedonia.  
Future directions. This work was done as part of a broader goal to elucidate the 
biological and neurological mechanisms implicated in MDD, and these results are the 
beginning of a larger investigation. Current research on the MDD is focusing, in part, on 
intracellular signaling, synaptic plasticity, and the glutamatergic system. The thyroid 
system – despite being notably crucial for many cellular processes and widely associated 
with depressive-like behaviors – has yet to be explicitly examined in this particular 
context. The preliminary behavioral evidence gathered here is supportive of a 
hypothyroid model inducing particular depressive-like symptoms, especially as they 
relate to anxiety on the EPM. Furthermore, the finding that thyroxine treatment 
normalized the amount of time spent in the EPM open arms suggests that addition of TH 
to the hypothyroid model had some antidepressant-like properties. For example, 
fluoxetine (Silva et al., 1999) and the AMPAR positive allosteric modulator S47445 
(Mendez-David et al., 2017) have been found to reverse this same effect.  
There is accumulating evidence that the glutamate receptor AMPA could be 
implicated in the robust antidepressant effects of ketamine (e.g. Koike et al., 2011, Zhou 




et al., 2014). Tissue slices from the prefrontal cortex, amygdala, and hippocampus were 
collected from the mice in the present study so that AMPA receptor binding can later be 
examined in this hypothyroid model (procedures further described in Appendices D and 
E). Treatment with antidepressants like fluoxetine, desipramine, and ketamine have all 
been associated with increased AMAPR expression in these regions (Du et al., 2006; 
Tizabi et al., 2012), so it will be exciting to see how binding is influenced by the PTU 
and thyroxine treatments. Additionally, AMPA expression can be studied in relation to 
the behavioral responses found in the current research. In sum, there is great potential for 
future research to examine TH function, depressive symptoms, and glutamate 
neurotransmission as they relate to one another. 
Conclusion  
The present study provides preliminary evidence that a model of hypothyroidism 
by administration of PTU can model symptoms of anxiety in the elevated plus-maze 
paradigm. Addition of the TH thyroxine prevented these anxiety-like effects induced by 
the hypothyroid model. This study did not find any effect of hypothyroidism on 
anhedonia, as measured in the saccharin preference test, or spatial memory, as assessed 
by the object placement test. However, a PTU/thyroxine combination treatment resulted 
in increased saccharin preference, which could be interpreted as an increase in the reward 
value of the sweetened solution. Future studies should examine how behavior is affected 
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Group Treatment Mean dose/day 
PTU PTU 53.04 mg/kg body weight 
PTU/thy PTU & thyroxine 87.57 mg/kg body weight 






Overview of Experimental Design 








Condition N Experimental Treatment 
PTU (hypothyroid) 15 Standard rodent chow + PTU (0.5 g/kg of chow) 
PTU/thyroxine 
(hyperthyroid) 
15 Standard rodent chow + PTU (0.5 g/kg of chow) + thyroxine 
(0.5 g/kg of chow) 
Control 15 Standard rodent chow 






Figure 1. Overview of the hypothalamic-pituitary-thyroid axis.  
Thyroid releasing hormone (TRH) produced in the hypothalamus is released to the 
anterior pituitary, stimulating the release of thyroid stimulating hormone (TSH). This 
initiates production of T3 and T4 in the thyroid gland. High levels of TH in the 















Figure 2. OPT Object Placements. 
Approximate positioning of each object during the information (A) and retention trials 
(B). One object (unshaded) remained in the same position across trials. The other 















































Nov 19 – Nov 25 Mouse age: 5 weeks 
 
Mice arrive at vivarium; 1-week acclimation period with 
standard chow 
 
Nov 26 – Dec 9 Mouse age: 6-7 weeks 
 
Acclimation period ends; mice put on control diet for 2 weeks. 
Weighed & handled twice a week. 
 
 
Dec 10 – Jan 6 Mouse age: 8-11  weeks 
 
Cages are randomly assigned to treatment groups, and mice 
receive ear notches for identification. Experimental treatment 
ensues for 4 weeks. 
 
Note: On 1/5, one PTU/thyroxine mouse was found deceased 
and another was put down 
  
Jan 7 – Jan 13 Mouse age: 12 weeks 
 
Behavioral testing. All mice remain on experimental diets. 
Mice complete saccharin habituation period, saccharin 
preference test, and EPM. All PTU/thyroxine mice were put 
down, and OP continued for PTU and control mice. 
 
Jan 14 – Jan 27 Mouse age: 13-14 weeks 
 
PTU and control mice sacrificed; plasma & tissue collected. 












Figure 4. Behavioral Measures on the Saccharin Preference Test. 
A) Mean saccharin preference scores (± SEM), expressed as a percentage of total water 
consumption. ***p<.001 in comparison to controls, and ++p<.01 compared to PTU 
(Kruskal Wallis Test, Mann-Whitney U post-hoc); n = 12 for PTU/thy, and 15 for PTU 
and controls. Dotted line represents 50% preference.  
B) Total combined consumption of saccharin and tap water (g), expressed mean ± SEM, 
*p<.05 compared to controls, ++p<.01 compared to PTU (one-way ANOVA, Tukey 
HSD).  N = 12, 14, and 15 for PTU/thy, PTU, and controls (respectively). One outlier 
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Figure 5. Behavioral Measures on the Elevated Plus-Maze  
A) Mean percentage of time spent in the open arms, relative to the closed arms of the 
maze (± SEM). *p<.05 and ++p<.01 in comparison to controls and PTU, respectively 
(one-way ANOVA, Tukey HSD); n = 12, 13, and 15 for PTU/thy, PTU, and controls. 
Two outliers were excluded from the PTU group. 
B) Total distance traveled in EPM (cm), expressed mean ± SEM, ++p<.01 compared to 
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Figure 6. Behavioral Measures on the Object Placement Test  
There were no significant differences between PTU and control mice in percent novel 
exploration time (A; N = 15 for both groups) or total exploration time (B; N = 14 PTU, 
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Figure 7. Mean Body Weights. 
Mean body weight (g) for each group throughout the duration of the experiment. Error 
bars represent standard error. There were significant main effects of mouse age (p < 
0.001) and treatment group (p = 0.01), and a significant age x group interaction (p < 
0.001; mixed ANOVA). PTU/thy mice weighed significantly less than the other two 























Figure 8. Mean Food Consumption.  
Mean food consumption (g) per mouse during each week of treatment, expressed mean ± 
SEM. PTU/thy mice were fed only through 11 weeks of age. Effects were significant for 
group and a group/age interaction (p < 0.01, mixed ANOVA). PTU/thy mice consumed 












Pilot Data for Behavioral Tests 
Table A1 
Saccharin Preference Pilot Data 
 
Note. Cages of mice (n=4, 5 mice per cage, 50% male) were left overnight with one 
bottle of tap water, and one bottle of either 0.01% or 0.03% saccharin solution. Bottles 
started with 200mL of solution and were weighed before and after the overnight period. 
Table A1 shows the amount of tap water consumed, the amount of saccharin solution 
consumed, and the total amount of solution consumed for each cage. Saccharin 
preference was calculated by dividing the amount of saccharin consumed by total 
consumption. The 0.03% solution seemed to yield a higher and more consistent saccharin 









Note. EPM pilot data was analyzed to determine whether the percentage of time spent in 
open arms remained stable across different trial lengths. Male mice (n=10) were each 
given 5-minute sessions in the maze. Video tracking data was examined up to the 3-
minute, 4-minute, and 5-minute marks. Because there was no significant difference in 
percentage of time spent in open arms across time points (f(2) = 0.035, p = 0.97), a 3-
minute trial length was chosen for the hypothyroid study tests. 
 
 








2 0.01% 59.06% 15 10.4 25.4 
3 0.01% 70.79% 20.6 8.5 29.1 
1 0.03% 77.85% 22.5 6.4 28.9 
4 0.03% 77.63% 22.9 6.6 29.5 
Trial Length 
(minutes) 
N Mean % of time in open arms SEM 
3 10 30.7% 0.034 
4 10 31.7% 0.032 
5 10 30.6% 0.033 





OP Pilot Data: Object Selection  
 
 
Note. For the object placement test, it was important to select an object stimulating 
enough to induce exploration in the mice. Male mice (n=10) were randomly assigned to 
explore one of two objects: a small ceramic white angel figurine, or a ceramic 
multicolored flamingo of roughly the same size. Mice were placed in an open field for 5 
minutes with two identical figurines of the assigned object. Overall, mice spent more 
time investigating the flamingo (mean time = 48.6 seconds ± 2.94 SEM) than the angel 
(mean time = 35.9 seconds ± 3.19 SEM). This difference proved significant in a t-test 
(t(16.42) = 2.94, p < 0.01). The flamingo figurines were therefore used for the 
hypothyroid study tests. 
  
Table A4 
OP Pilot Data: Inter-Trial Interval 
 
Note. Male mice (n=10) underwent the object placement task twice, on separate days. In 
the first session, there was a 60-minute delay between the information and retention 
trials. In the second session, the delay was reduced to 30 minutes. Percentage of novel 
placement exploration time in retention trials did not differ based on the inter-trial 
interval (t(17.61) = 0.51, p = 0.62). A 60-minute ITI was chosen for hypothyroid study 







Object N Mean exploration time 
(seconds) 
SEM 
Flamingo 6 48.6 2.94 
Angel 4 35.9 3.19 
ITI (minutes) N Mean % novel placement 
exploration time 
SEM 
30 10 62.6% 2.84 
60 10 60.7% 2.45 





OP Pilot Data: Novel Object Placement  
 
Note. A subset of mice (n = 6) underwent the object placement test with the modified 
object placements and a 60-minute ITI. There was no difference in percentage of novel 




Figure A1. OP Pilot Data: Approximate Object Placement 
 
It became apparent that preference for the novel object placement could alternatively be 
explained by a preference for the arena corners. Object placements were modified so that 
during retention trials, novel and familiar objects were approximately the same distance 
from a corner of the field. Figure A1 shows the old and modified object placements for 






Object Placement N Mean % novel exploration time SEM 
Modified Placement 6 62.7% 2.06 
Original Placement  10 60.7% 2.45 
Original Object Placement Modified Object Placement 
  
Information trial Retention Trial Information trial Retention Trial 





Apparatus Measurements  
Figures B1 and B2 are scaled depictions of the apparatus used in the EPM (Figure 




















Figure B1. Elevated Plus Maze Dimensions 
Figure B2. Object Placement Field Dimensions 





Investigating Solution Spillage in the Saccharin Preference Test 
As noted in the Methods section, there was a concerning amount of solution 
spillage during the saccharin preference test. Tap water and saccharin solution tended to 
drip out of the testing bottles as they were placed into the cages. Because the bottles were 
very sensitive to even the smallest amounts of pressure, we were concerned that the 
solutions were also dripping throughout the night in response to natural mouse 
movement.  
The obtained preference test results seemed to verify these concerns. Across all 
treatment groups, mice had an average mean solution consumption of 16.44g ± 0.41 
SEM. Average body weight during the week of saccharin testing was 23.21g ± 0.39 
SEM. This means that on average, mice would have been drinking 70.83% of their body 
weight in a 12-hour period — a number which we find extremely unrealistic. An 
empirical spillage test was conducted to further investigate this issue. 
Twenty-four empty cages were fit with two bottles of solution – 200mL of tap 
water, and 200mL of 0.03% saccharin solution. The bottles of saccharin were randomly 
assigned to the right or left side of the cage. Cages were prepared and handled in an 
identical manner to how they were handled in the saccharin preference test. They were 
left on the same storage racks used in the behavioral tests for the same 12-hour overnight 
period. Bottles were weighed before and after the testing period to measure the amount of 
solution lost. 
Average spillage was 9.22g ± 0.6 SEM for saccharin-filled bottles, and 10.56g ± 
0.29 SEM for tap-filled bottles. Differences between saccharin and tap spillage did not 




quite reach significance (t(32.93)  =  -2.02, p = 0.052); but the higher variance among 
saccharin spillage values (2.94 vs. 1.40 SD) and near-significance in the t-test made us 
suspect that the spillage characteristics could differ between the two solutions, possibly 
due to different surface properties. We hoped to obtain more accurate consumption 
values by subtracting the obtained consumption amounts by average spillage. This proved 
to be problematic, however, as mice consumed less solution than average spillage in 
several cases. 
Concerns about spillage were ultimately dismissed for two reasons. First, a 
Lilliefors test revealed that spillage values were normally distributed (D = 0.08, p = 
0.63). Second, there was no reason to suspect that spillage amounts differed between 
mice of different treatment groups. We reasoned that while solution spillage may have 
affected the total consumption or saccharin preference values, it is unlikely that the 
degree of difference among treatment groups was compromised. We therefore decided to 
report our saccharin preference and consumption values as measured, with the 
assumption that any potential spillage should have been randomly distributed across 
cages. Still, one should be aware that the measures of saccharin and tap consumption 












Methods for Tissue Sectioning  
Slides were created with tissue slices from the hippocampus and prefrontal cortex 
for binding experiments. Slices were cut 10 micrometers thick along the coronal axis with 
a cryostat. Paxinos and Franklin’s (2012) neuroanatomical atlas was used for reference, 
which estimates the location of specific brain structures relative to landmarks on the 
mouse skull. The present study found regions of interest based on their positioning from 
Bregma, which is the central point on the skull where the sagittal and coronal sutures 
intersect. Slices approximately 2mm to 1.4mm anterior to Bregma were used for the 
prefrontal cortex—a range estimated by Paxinos and Franklin (2012). A literature search 
was conducted to determine an optimal range for the hippocampal tissue, as it was 
imperative to use locations related to spatial memory function. There is evidence that 
lidocaine injections blocked spatial memory in mice when injected in the hippocampal 
CA1 region, -2.0mm from Bregma (Assini, Duzzioni, & Takahashi, 2009). Another study 
found impaired spatial learning in mice with hippocampal lesions from -1.0 to -3.5mm 
(Cho, Friedman, & Silva, 1998). This study used a range of approximately -1.3mm, 
which also included areas of the amygdala implicated in the EPM. Slices were mounted 
onto glass slides, and approximately 12 tissue slices were collected per region for each 










Examining AMPA Receptor Binding: Overview of Autoradiography and 
Proposed Methods 
AMPA receptor binding in the prefrontal cortex, hippocampus, and amygdala will 
be measured using autoradiography. This technique involves labeling ligands with 
radioactive isotopes to study their binding patterns with the receptors of interest. 
Radioligand experiments and based on the law of mass action, which assumes that the 
ligand can both bind (associate) and dissociate with a given receptor (binding is thus 
assumed to be reversible). In this model, equilibrium is said to be achieved when the rate 
at which ligand/receptor complexes are formed and the rate at which they dissociate are 
equal. One way to quantify AMPA receptor binding is to determine the amount of 
specific binding of the radioligand at equilibrium using different radioligand 
concentrations. Because radioligands bind to nonreceptor sites as well as the receptors of 
interest—referred to as nonspecific binding—the amount of nonspecific binding must be 
measured first, and then subtracted from the total binding amount. Nonspecific binding 
can be determined by using an unlabeled drug at a sufficiently high concentration that 
will bind to virtually all the receptors of interest. Since the drug will occupy all the 
receptor sites, binding of the radioligand will be nonspecific and specific receptor binding 
can be calculated (Motulsky, 1996). 
Specific binding at different concentrations of the radioligand can be plotted, and 
the data can be used to determine the total receptor number. This value, or the B(max), 
represents total receptor density expressed in fmol of the radioligand per mg of tissue. In 
this study, the B(max) will quantify AMPA receptor binding as the primary dependent 




variable. [3H]AMPA will be used to label AMPA receptors in the sectioned brain tissue. 
The tissue will be tested for total and nonspecific binding at different concentrations of 
the radioligand (likely 1, 3, and 10nm). A phosphor screen will be used to collect 
radioactivity, and the slides will be put in a phosphor imager. Radioactivity can be 
quantified by the amount of fluorescence detected per unit of area. Average intensity 
from the nonspecific conditions will be subtracted from the total binding condition to 
produce a measure of specific binding at each concentration of the radioligand. These 
measurements can generate the B(max), or receptor density, which can be compared 




















Data with Outliers Included 
 There were several cases where, while behavioral data was being analyzed, 
outliers were identified using Pierce’s criterion. It was decided a priori that these values 
would be excluded from the final analyses reported in the Results section. The following 
tables show statistical results including outliers for “percent open” scores in the elevated 
plus-maze, and total consumption scores in the saccharin preference test. In both cases, 
the overall differences remain significant. There were also outliers removed for total 
exploration scores in the object placement test, but those differences were not significant 
with or without outlier data. 
 
Table E1 
EPM Percent Open Scores Including Outliers  
 df Sum of Squares Mean Square F p 
Group 2 0.136 0.068 4.389 0.02 
Residuals  39 0.604 0.015   
 
Note. A Tukey post-hoc revealed that PTU mice spent a significantly smaller percentage 
of time in the open arms (m=8.67% ± 0.03 SEM compared to 22.5% ± 0.04 SEM; p = 
0.02). However, the difference between PTU and control mice was no longer significant 












Total Consumption in Saccharin Preference Test Including Outliers  
 
 
Note. A Tukey post-hoc revealed that PTU/thy mice consumed significantly more 
solution than PTU mice (m=18.5g ± 1 SEM compared to 14.9g ± 0.35, p < 0.001). 
However, the difference between PTU/thy and control mice was no longer significant, 
















 df Sum of Squares Mean Square F p 
Group 2 84.8 42.4 7.93 0.0013 
Residuals  39 208.6 5.35   
